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In multicellular organisms, proper control of cell death is important for 
processes such as embryonic development and turnover of adult tissues. 
Misregulation of cell death contributes to many diseases, including cancer. 
Human cancers frequently show defects in their ability to initiate or execute 
apoptotic cell death, making them resistant to many currently available 
chemotherapeutic agents that target apoptosis. It is therefore of interest to 
discover alternative cell death programs that may be exploited to specifically 
eliminate tumor cells.  
 
This thesis defines a new form of cancer cell death induced by the small 
molecule erastin. Erastin is a quinazolinone derivative that was originally 
identified in a screen for small molecules that are synthetic lethal with the RAS 
oncogene. In cancer cells with oncogenic RAS-RAF-MEK signaling, erastin 
induces an iron-dependent, oxidative cell death that lacks hallmarks of classical 
apoptosis. We refer to this type of cell death as ferroptosis. In this thesis I 
characterize ferroptosis with respect to other cell death phenotypes and find that 
  
it is distinct from previously described cell death paradigms such as apoptosis, 
autophagic cell death, accidental necrosis, and various forms of programmed 
necrosis. Ferroptosis involves generation of death-inducing reactive oxygen 
species (ROS), and I show that this ROS production depends upon activity of 
NADPH oxidase-1 and pentose phosphate pathway-derived NADPH.  
 
Erastin is a ligand for the mitochondrial-resident voltage-dependent anion 
channel-2 and -3 proteins (VDAC2,3), and expression of VDAC2,3 is necessary 
for ferroptosis. I describe a functional assay we have developed to investigate 
the erastin-VDAC interaction. Erastin increases the permeability of purified 
VDAC2 to an endogenous substrate, NADH. Finally, by screening over fifty 
erastin analogs for the ability to induce ferroptosis, I have defined regions of the 
molecule required for activity and identified other parts of the molecule that may 
be modified to improve erastin’s pharmacologic properties as a potential anti-
tumor agent.
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Observations of physiologic and pathologic tissue remodeling in living 
organisms date back to at least the Greeks, who are credited with describing 
regression of fetal heart tissues following birth (Clarke and Clarke 1996). In 1842 
Vogt described for the first time the modern idea that tissue metamorphosis 
involves death of individual cells. In studies of the developing toad, he observed 
individual cells of the notochord being “resorbed” or “destroyed” as cartilage and 
vertebrae developed. Several decades of research confirmed that Vogt’s 
observation was generalizable to many tissue types and organisms. This work 
inspired the search for stimuli that lead individual cells to die (Saunders 1966; 
Ellis and Horvitz 1986). Lockshin is generally credited with coining the term 
“programmed cell death,” which conveys the idea that mechanisms for carrying 
out cell death can be inherent to the dying cell itself (Lockshin and Williams 
1964). The field of cell death research greatly accelerated in the second half of 
the twentieth century with genetic and biochemical characterizations of several 
mechanisms of cell death. Furthermore biomedical researchers began to realize 
the importance of cell death in many classes of disease, including cancer, 
autoimmunity, ischemic injury, and neurodegeneration (Vaux, Cory et al. 1988; 
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Thompson 1995). Understanding the role of improperly regulated cell death in 
these diverse pathologies became an important step in developing new 
therapeutics for a wide range of diseases.  
 
Major forms of cell death 
 Historically cell death has been categorized based on morphologic 
observations. Three major forms of cell death are recognized to date: apoptosis 
(type I cell death), autophagy (type II), and necrosis (type III or accidental cell 
death) (Galluzzi, Maiuri et al. 2007; Kroemer, Galluzzi et al. 2009). Below I 
describe the contexts and features of these three phenotypes of cell death.  
 
Apoptosis 
 The term “apoptosis” was coined in 1972 by Kerr, Currie, and Wyllie to 
describe a characteristic morphology of cell death observed in both developing 
and adult animal tissues as well as in pathologic settings.  This phenotype of cell 
death involves cellular shrinkage, nuclear condensation with DNA fragmentation, 
and packaging of the cytoplasmic contents into individual membrane-bound 
apoptotic bodies, which are shed from the surface of the dying cell (Kerr, Wyllie 
et al. 1972; Wyllie 1980). Neighboring cells subsequently recognize plasma 
membrane changes in apoptotic bodies and engulf them in a non-inflammatory 
manner (Fadok, Voelker et al. 1992). 
 Genetic control of apoptosis was described by Horvitz and colleagues 
based on studies in the nematode C. elegans. In animals with mutations to the 
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ced-3, ced-4, and ced-9 genes, well-defined developmental cell deaths did not 
occur and adults contained additional surviving cells (Ellis and Horvitz 1986; 
Hengartner, Ellis et al. 1992). Continuing studies of CED-3 demonstrated 
homology to the mammalian interleukin-1ß converting enzyme (ICE), a cysteine 
protease (Thornberry, Bull et al. 1992; Yuan, Shaham et al. 1993). Subsequent 
investigations in mammalian cells identified a family of cysteine proteases 
implicated in induction of apoptosis and proper mammalian development 
(Fernandes-Alnemri, Litwack et al. 1994; Tewari, Quan et al. 1995; Kuida, Zheng 
et al. 1996; Orth, Chinnaiyan et al. 1996). These enzymes were eventually 
designated “caspases,” to reflect their status as cysteine proteases that cleave 
substrates after an aspartic acid (Alnemri, Livingston et al. 1996). The caspases 
are synthesized as pro-enzymes that are activated upon hydrolysis of an 
inhibitory N-terminal domain. In response to apoptotic stimuli, initiator caspases 
such as caspase-8 and -9 are cleaved; these then catalyze cleavage and 
activation of downstream effector caspases such as caspases-3, -6, and -7 in 
what has come to be termed the caspase cascade (Cohen 1997). Activated 
caspases hydrolyze essential cellular proteins such as DNA repair and 
cytoskeletal proteins, resulting in some of the classic features of apoptosis 
including alterations in nuclear morphology and cell shrinkage (Casciola-Rosen, 
Nicholson et al. 1996; Kothakota, Azuma et al. 1997). 
 Many different stimuli promote activation of caspases. These include 
growth factor withdrawal, ionizing radiation, and death-inducing cytokines. 
Broadly speaking, initiation of apoptosis can occur through two distinct pathways: 
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initiation from an extrinsic stimulus or an intrinsic stimulus. Ligands of the tumor 
necrosis factor (TNF) receptor superfamily (Pfeffer, Matsuyama et al. 1993), 
including the well-studied Fas/Fas-ligand (FasL) interaction in peripheral 
lympocytes, are common initiators of the extrinsic pathway of apoptosis. 
Fas/FasL signaling mediates removal of self-reactive T cells as well as cytotoxic 
functions of CD8+ T cells, and mice with mutations in the cytoplasmic domain of 
Fas exhibit lymphoproliferative disorders (Brunner, Mogil et al. 1995; Abbas and 
Lichtman 2004). When Fas encounters membrane-bound FasL, the cytoplasmic 
domains of Fas organize and recruit members of a death-inducing signaling 
complex such as the death domain protein FADD and caspase-8 (Chinnaiyan, 
O'Rourke et al. 1995; Muzio, Chinnaiyan et al. 1996). Cleavage of caspase-8 
releases the active form of the protease, which can subsequently activate 
downstream effector caspases as well as additional pro-apoptotic proteins like 
Bid (see below).  
Within cells mitochondria are a critical locus of control of the intrinsic 
pathway of apoptosis. Mitochondrial outer membrane permeablization (MOMP) 
releases a number of factors that trigger caspase activtation. MOMP is regulated 
by members of the Bcl-2 family of proteins, which have in common one to four 
Bcl-2 homology domains (BH domains). The Bcl-2 family includes agonists and 
antagonists of apoptosis; these proteins fall into three major classes. The first 
class of proteins includes the multidomain pro-apoptotic Bcl-2 family members 
Bax and Bak. These proteins are thought to be essential for pore formation in the 
mitochondrial outer membrane and thereby initiate MOMP (Oltvai, Milliman et al. 
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1993; Wei, Zong et al. 2001; Kuwana, Mackey et al. 2002). A second set of pro-
apoptotic Bcl-2 family members includes the BH3-domain only proteins, such as 
Bid and Bad (Wang, Yin et al. 1996; Datta, Dudek et al. 1997). The BH3-only 
proteins promote apoptosis by binding to and activating Bax and Bak while 
preventing sequestration of Bax and Bak by anti-apoptotic Bcl-2 proteins. Finally 
the anti-apoptotic Bcl-2 family members include Bcl-2 (the mammalian homolog 
of ced-9), Bcl-XL, and others (Vaux, Weissman et al. 1992). The anti-apoptotic 
Bcl-2 proteins protect the mitochondria from permeablization by Bax and Bak, 
possibly by sequestering Bax/Bak directly or by sequestering BH3-only proteins 
required for Bax/Bak activation (Green 2006). 
MOMP leads to release of intermembrane space proteins that initiate 
caspase activation. For example, when released to the cytosol, the electron 
transport chain protein cytochrome c assembles with apoptotic protease 
activating factor-1 (Apaf-1) in an ATP-dependent manner to form the 
apoptosome (Liu, Kim et al. 1996). Initiator caspase-9 is recruited to the 
apoptosome and activated, such that it can then cleave and activate downstream 
effector caspases -3 and -7 (Zou, Li et al. 1999). In addition to cytochrome c, 
MOMP liberates other mitochondrial proteins such as Smac/DIABLO. In the 
cytosol, Smac/DIABLO blocks the activity of a family of Inhibitor of Apoptosis 
Proteins (IAPs) that normally negatively regulate caspase activation (Deveraux, 





 Autophagic cell death refers to cell death with a morphology of extensive 
cytoplasmic vacuole formation. This morphology is observed in mammalian 
embryos both during development and after exposure to certain toxins 
(Schweichel and Merker 1973). During macroautophagy (hereafter referred to as 
autophagy), the cell envelopes its own cytoplasmic contents and organelles in 
double-membrane autophagic vacuoles called autophagosomes. Upon fusion of 
the autophagosome with the lysosome, the contents are digested by lysosomal 
hydrolases. Autophagy allows turnover and recycling of damaged organelles and 
also is a mechanism by which cells can survive periods of starvation. This 
process has been observed across eukaryotes, from yeast to plants and 
mammalian cells and under a range of developmental, environmental, or 
pathologic conditions (Beaulaton and Lockshin 1982; Klionsky and Emr 2000). In 
mammalian cells autophagy can also be induced by growth factor deprivation, 
even in the presence of abundant extracellular nutrients (Lum, Bauer et al. 2005).  
Autophagosome formation is governed by the ATG genes. These genes 
were originally identified in Saccharomyces cerevisiae mutants that showed 
increased sensitivity to nitrogen starvation (Tsukada and Ohsumi 1993). The 
ATG gene products regulate membrane rearrangements necessary for 
autophagosome formation through a series of protein conjugation events 
(Mizushima, Noda et al. 1998). Homologs identified in C. elegans and mammals 
also have roles in the response to starvation. For example Atg5-/- neonatal mice 
have decreased plasma amino acid levels and reduced survival to fasting 
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following birth (Kuma, Hatano et al. 2004). The mammalian homolog of yeast 
ATG6, beclin-1, promotes autophagosome formation in breast carcinoma cells 
and inhibits the potential of cells to form tumors in mice (Liang, Jackson et al. 
1999).  
In mammalian cells autophagy is negatively regulated by the mammalian 
target of rapamycin (mTOR), a serine-threonine kinase (Brown, Albers et al. 
1994; Sabatini, Erdjument-Bromage et al. 1994; Noda and Ohsumi 1998; 
Kamada, Funakoshi et al. 2000). Growth factor signaling is transduced from 
class I phosphatidylinositol-3-kinases (PI3K) via Akt to activate mTOR. mTOR 
exerts growth-promoting effects through downstream targets such as p70S6-
kinase, a regulator of translation machinery, and the translation initiation inhibitor 
4-EBP1. Inhibition of mTOR by growth factor withdrawal or rapamycin treatment 
leads to a decrease in phosphorylation of S6 kinase and induction of autophagy 
(Blommaart, Luiken et al. 1995). In yeast, Tor signaling also negatively regulates 
association of Atg1-Atg13, a step required for membrane organization and 
autophagosome formation (Noda and Ohsumi 1998; Kamada, Funakoshi et al. 
2000). 
 Although autophagic vacuoles are frequently observed in dying cells, the 
precise role of autophagy in mammalian cell death (and existence of a true 
“autophagic cell death”) is presently a matter of debate (Edinger and Thompson 
2004; Galluzzi, Maiuri et al. 2007; Yuan and Kroemer 2010). Studies in model 
organisms have found that intact functioning of autophagy is necessary for 
complete physiologic cell death of the salivary gland of Drosophila melanogaster 
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during development (Berry and Baehrecke 2007). However, whether the 
autophagic machinery itself has the capacity to direct cell-autonomous death is 
unclear. In mammalian cells autophagic vacuoles are frequently observed 
simultaneously with caspase-dependent apoptosis (Galluzzi, Maiuri et al. 2007), 
and it has been argued that as a survival mechanism autophagy is often induced 
by the same stresses that trigger cell death by other pathways. In tumor cells 
with disrupted apoptotic machinery, autophagy buffers metabolic stress and 
prevents necrosis (Degenhardt, Mathew et al. 2006). However other work shows 
that genes mediating autophagy, such as beclin-1, are necessary for cell death in 
the presence of caspase inhibition and suggests that autophagy is a backup 
option for execution of cell death when apoptosis is inhibited, such as by viral 
pathogens or in tumors (Yu, Alva et al. 2004). Clearly autophagy is significant in 
the balance between cell survival and cell death, but the ability of autophagy to 
independently direct mammalian cell death remains to be clarified.  
 
Necrosis 
Necrosis has traditionally been thought of as an accidental and disordered 
cell death occurring upon severe cellular stress, such as ischemia or extreme 
temperature changes, or exposure to toxic conditions, such as detergents 
(Hotchkiss, Strasser et al. 2009). The morphology of necrosis is characterized by 
cytoplasmic and organelle swelling and early loss of plasma membrane integrity 
(Schweichel and Merker 1973; Clarke 1990). In vivo spilling of cytoplasmic 
contents into the extracellular environment provokes inflammation and an 
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immune response, which is typically not observed following apoptosis (Zong and 
Thompson 2006). In contrast to apoptosis, a clear genetic basis has not been 
described for classical necrosis, although several distinguishing subcellular 
events and mediators have been identified (Golstein and Kroemer 2007). One 
difference between apoptosis and necrosis is that necrosis frequently involves 
bioenergetic collapse. Necrotic death is observed when cells lack nutrients and 
oxygen necessary to generate ATP, such as in the internal regions of growing 
tumors, or in cell culture models pre-depleted of ATP (Leist, Single et al. 1997). 
Abrupt changes to membrane-bound organelles also occur during necrosis. 
Opening of the mitochondrial permeability transition pore (mPTP) increases 
permeability of the inner membrane to solutes of up to 1.5 kDa and allows 
mitochondrial swelling (Crompton, Virji et al. 1998; Baines, Kaiser et al. 2005). 
The PTP plays a role in necrotic death following ischemia-reperfusion injury and 
some bacterial infections (Baines, Kaiser et al. 2005; Carneiro, Travassos et al. 
2009). In oxidative stress-induced necrosis, rapid lysosomal membrane 
permeabilization and amplification of reactive oxygen species are observed 
(Berghe, Vanlangenakker et al. 2010). Finally, non-caspase proteases such as 
the calcium-activated calpains and the lysosomal cathepsins have been 
implicated in execution of necrosis in vivo. In C. elegans models of necrotic 
neurodegeneration cell death is suppressed by deficiencies in calpains and 
cathepsins. (Syntichaki, Xu et al. 2002; Artal-Sanz and Tavernarakis 2005). 
Interestingly recent studies have shown that not all cell deaths with 
necrotic morphology are accidental and irreversible. Some forms of necrosis 
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appear to be carried out in response to specific stimuli and involve particular 
signaling pathways and mechanisms of cell destruction. The term “programmed 
necrosis” has been used to describe such forms of non-apoptotic cell death. The 
most well-studied example of programmed necrosis is necroptosis. Necroptosis 
is a death receptor-stimulated death that occurs in the absence of caspase 
activation (Holler, Zaru et al. 2000). The receptor interacting protein-1 (RIP1) is a 
key mediator of necroptosis, and several other modulators have been identified, 
including RIP3 (Degterev, Hitomi et al. 2008; Hitomi, Christofferson et al. 2008; 
Cho, Challa et al. 2009). In an analogy to the caspase cascade of apoptosis, 
execution of necroptosis appears to be controlled by a cascade of downstream 
kinase signaling (Declercq, Vanden Berghe et al. 2009). Necroptosis has been 
observed in animal models of several pathologies, including ischemic injury and 
viral infection (Leist and Jaattela 2001; Degterev, Huang et al. 2005; Cho, Challa 
et al. 2009). The example of necroptosis illustrates that programmed necrosis 
may be more important than previously thought in pathologic cell death and 
makes the case that a better understanding of the spectrum of cell death 
phenotypes may have therapeutic applications to particular diseases.  
 
Alternative cell death pathways 
In higher eukaryotes and mammalian cell culture, cell death phenotypes 
intermediate between caspase-dependent apoptosis and accidental necrosis 
have been observed (Leist and Jaattela 2001; Yuan and Kroemer 2010). 
Investigations of these phenotypes have revealed the plasticity of known cell 
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death signaling as well as identified new cell death initiators and effectors. Other 
work has revealed several seemingly completely distinct forms of cell death in 
vivo in specific cell and tissue contexts. Several examples are summarized 
below.  
 
Caspase-independent cell death 
 In higher eukaryotes, cell death with morphologic features of apoptosis 
can occur in the absence of effector caspase activation (Leist and Jaattela 2001). 
This phenomenon is possible because of redundant mechanisms for executing 
apoptotic-like death. Non-caspase proteases such as calpains or cathepsins may 
substitute as effectors of cell death in the setting of caspase inhibition 
(Foghsgaard, Wissing et al. 2001). The mitochondria play an important role in 
regulating caspase-independent apoptosis, as several mitochondrial-resident 
proteins are involved in this form of cell death. For example, the DNA-cleaving 
enzyme endonuclease G is released from the mitochondrial intermembrane 
space and hydrolyzes nuclear DNA without a requirement for caspase activation 
(Li, Luo et al. 2001). The flavoprotein apoptosis inducing factor (AIF) is also 
released from the mitochondrial intermembrane space upon induction of 
apoptosis and mediates cell death during embryonic cavitation that has 
morphologic similarity to apoptosis but does not require the apoptosome or 





Additional forms of programmed necrosis 
In addition to necroptosis, other forms of programmed necrosis have been 
described in specific cell types and contexts. For example, in Bax-/- Bak-/- 
knockout MEFs, severe DNA damage induces cell death with necrotic features 
(Zong, Ditsworth et al. 2004). Bioenergetic failure due to overactivation of the 
DNA repair enzyme PARP-1 is responsible for this type of cell death. 
Interestingly sensitivity to PARP-dependent necrosis appears to be determined 
by the metabolic state of the MEFs; cell death is prevented when cells are grown 
in conditions that favor oxidative phosphorylation based metabolism rather than 
glycolytic metabolism (Zong, Ditsworth et al. 2004).  
The proapoptotic cytokine TNF can induce necrosis in mouse 
fibrosarcoma cells that involves production of reactive oxygen species. The 
superoxide-producing enzyme NADPH oxidase-1 (NOX1) has been implicated in 
this type of programmed necrosis (Kim, Morgan et al. 2007; Berghe, 
Vanlangenakker et al. 2010; Vanlangenakker, Vanden Berghe et al. 2010). In 
TNF-induced necrosis NOX1 is found within a signaling complex containing RIP1 
and riboflavin kinase (RFK) (Yazdanpanah, Wiegmann et al. 2009). TNF 
stimulation leads to superoxide production and subsequent sustained JNK 
activation, which is essential for death (Kim, Morgan et al. 2007). 
 
Cell deaths with unique properties: entosis and NETosis  
Forms of cell death with completely distinct morphologies from apoptosis, 
autophagy, and necrosis have also been described. The recently-coined term 
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“entosis” describes a process in which live, matrix-detached cancer cells become 
internalized within neighboring non-phagocytic epithelial cells (Overholtzer, 
Mailleux et al. 2007). The cell-within-cell phenotype has long been observed in 
tumor pathology samples (Gupta and Dey 2003). The internalized cells of entosis 
lack hallmarks of apoptosis, such as phosphatidylserine exposure, and may be 
digested by the lysosomes of the cell they are within or they may be released 
and survive. Entosis is thought to be driven by unbalanced forces at the 
adherens junctions between the two cells and require cytoskeletal remodeling in 
the internalizing cell. An intriguing form of cell death has also recently been 
described in human neutrophils. NETosis refers to neutrophil cell death in which 
the nuclear envelope disintegrates and chromatin is released into the 
extracellular environment as “nets” to trap invading bacteria (Brinkmann, 
Reichard et al. 2004; Fuchs, Abed et al. 2007). In summary, the number of 
observed ways cells die is increasing and it is likely that there are cell death 
pathways that have yet to be elucidated.  
 
Cell Death In Cancer 
 Evasion of apoptosis is one of the hallmarks of cancer (Hanahan and 
Weinberg 2000). Tumor cells develop and thrive under conditions of 
dysregulated cell cycle, decreased accessibility to nutrients and growth factors, 
oncogene expression, and genomic instability--conditions that could normally 
trigger apoptosis in healthy cells. Disruptions of the cell death machinery allow 
tumor cells to proliferate in spite of these stresses. A high percentage of tumors 
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(> 50%) have inactivation of the p53 pathway, and patients with inherited defects 
in p53 are prone to multiple neoplasms (Hollstein, Sidransky et al. 1991; 
Hotchkiss, Strasser et al. 2009). p53 normally senses cell stress such as DNA 
damage and activates transcription of multiple pro-apoptotic genes including bax, 
noxa, and puma (Miyashita and Reed 1995; Nakano and Vousden 2001; Yu and 
Zhang 2005). Apoptosis may also be suppressed in tumors by increased 
expression of anti-apoptotic signals. The MOMP antagonist Bcl-2 was originally 
identified as a proto-oncogene in B-cell lymphomas (Vaux, Cory et al. 1988; 
Strasser, Harris et al. 1990). In addition to these examples, many other genetic 
and epigenetic alterations in tumor cell apoptotic machinery have been identified 
(Weinberg 2007). Resistance to apoptosis through inactivation of inducers of 
apoptosis, increased expression of anti-apoptotic proteins, or increases in pro-
survival signaling are thought to be partially responsible for the resistance some 
tumors show to clinically used chemotherapeutics (Fisher 1994; Lowe, Bodis et 
al. 1994; Bunz, Hwang et al. 1999). One therapeutic strategy to address this 
problem is to restore cancer cell sensitivity to apoptosis by, for example, 
inhibiting negative regulators of apoptosis (Fesik 2005). An additional and 
complementary strategy is to identify additional cell death pathways to which 
tumor cells show increased susceptibility and find ways to induce these 
alternative forms of cell death in vivo. 
 




Use of small molecules in the study of cell death 
In addition to classical genetic and biochemical techniques, small 
molecules have historically been invaluable in the study of cell death. 
Staurosporine, a broad spectrum kinase inhibitor, has been widely used to 
induce and characterize apoptosis in many cell types (Bertrand, Solary et al. 
1994). The bacterial macrolide rapamycin facilitated studies of autophagy and led 
to identification of the protein TOR as a master regulator of autophagy (Brown, 
Albers et al. 1994; Sabatini, Erdjument-Bromage et al. 1994; Noda and Ohsumi 
1998). More recently, identification of the compound necrostatin-1 (Nec-1) 
highlighted the regulated nature of a previously observed form of necrotic cell 
death involving death-receptor signaling in the absence of caspase activation 
(Holler, Zaru et al. 2000) (Degterev, Huang et al. 2005). Studies of this cell death 
phenomenon, termed necroptosis, have demonstrated roles for the RIP1 and 
RIP3 kinases (Degterev, Hitomi et al. 2008) (He, Wang et al. 2009) (Cho, Challa 
et al. 2009) and have shown that necroptosis is relevant in multiple in vivo 
disease models including ischemic injury following stroke and the innate immune 
response to viral infection (Degterev, Huang et al. 2005) (Cho, Challa et al. 
2009). These studies and many others have revealed the plasticity of cell death 
processes, and it is likely that there are still more modes of cell death that could 




Forward Chemical Genetics 
 One way to identify new small molecule tools for the study of cell death is 
through a chemical genetic screen. Chemical genetics describes the study of 
gene function using chemical tools, such as small molecules, which alter the 
functions of proteins to which they bind (Schreiber 1998). In a classical genetic 
screen, the genome of a particular organism is randomly mutagenized and 
mutants are screened for a phenotype of interest. By analogy a forward chemical 
genetic approach uses small molecules, one at a time, to perturb organism 
function (Stockwell 2000; Walsh and Chang 2006). Libraries of small molecules 
or other chemical tools are assembled and screened for those compounds that 
yield the phenotype of interest. Following identification of screen hits, follow up 
studies are performed to understand how each hit induces the phenotype. This 
phase of forward chemical genetics often involves identification of the 
macromolecular target of the small molecule. Forward chemical genetic screens 
offer a number of advantages. First, they offer an unbiased approach to identify 
novel gene products (or targets) involved in a phenotype of interest. Second, the 
use of small molecules may complement classical genetic techniques in 
revealing alternative functions of a particular gene product (Knight and Shokat 
2007). Third, chemical genetics may be used in biological systems are less 
amenable to traditional genetic techniques, such as mammalian cell culture. 
Finally, an additional benefit of chemical genetic screens in disease models is 
that the small molecule hits may become lead-like compounds in development of 
a drug treatment for a particular disease (Hartwell, Szankasi et al. 1997).  
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One type of chemical genetic screen is a synthetic lethal screen (Walsh 
and Chang 2006). Synthetic lethality describes the relationship between two 
genetic mutations when each alone is compatible with cell (or organism) viability 
but together they result in death (Kaelin 2005). In chemical genetics one of the 
genetic mutations is replaced with a chemical perturbation such as a small 
molecule. Because the phenotype is cell death, synthetic lethal screening can 
provide new insights into gene products involved in mammalian cell death. In 
identification of new cancer cell death pathways, synthetic lethal screening 
provides the additional advantage of selecting events that occur in the context of 
a tumor genotype. Small molecule hits from these screens can then become 
chemical probes for further studies of cancer biology.  
 
Discovery of the small molecule erastin 
Erastin is synthetic lethal with oncogenic RAS 
The RAS oncogenes are mutated in approximately 25% of human tumors, 
particularly in lung, colon, and pancreatic cancers (Downward 2003; Malumbres 
and Barbacid 2003). Activating mutations of these small GTPases or their 
downstream signaling partners such as the RAF/MAPK pathway and the 
PI3K/AKT pathway lead to deregulation of cell proliferation, increased cell 
survival, and increased tumor invasiveness. There have been a variety of efforts 
to target the RAS proteins directly, but many of these have been unsuccessful in 
human trials. Understanding the unique biochemical features that distinguish 
tumors expressing oncogenic RAS from those expressing wild-type RAS is of 
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great interest, as these studies will provide new ways to target the large number 
of RAS-driven tumors.  
In a chemical genetic screen for small molecules showing synthetic 
lethality for oncogenic RAS, the Stockwell lab previously isolated the 
quinazolinone compound erastin (Figure 1.1A) as well as two additional 
structurally distinct compounds, RSL3 and RSL5 (Dolma, Lessnick et al. 2003; 
Yang and Stockwell 2008). These compounds show selectivity for cells with 
activated RAS, as they are much less potent in isogenic cells lacking mutant 
RAS (Figure 1.1B) (Hahn, Counter et al. 1999). To date erastin is the most well-
characterized of these compounds, although the three small molecules appear to 
act through similar, though not identical, mechanisms (Wolpaw, Shimada et al. ; 
Yang and Stockwell 2008).  
Erastin evoked particular interest because it induced death in a manner 
distinct from classical apoptosis. Evaluation of cell morphology revealed that 
erastin treated cells do not undergo shrinkage nor do they undergo chromatin 
margination and nuclear fragmentation (Dolma, Lessnick et al. 2003; Yagoda, 
von Rechenberg et al. 2007). From a functional standpoint, the primary 
distinguishing feature of apoptosis is activation of the caspases. Erastin-induced 
death shows no evidence of activation of effector caspases by western blotting, 
fluorogenic substrate assays, or rescue with pan-caspase inhibitors (Yagoda, von 
Rechenberg et al. 2007), K. Shimada and B.R.S. unpublished.) Erastin does not 
induce features of MOMP, such as cytochrome c release from the mitochondria, 
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Figure 1.1: Identification and characterization of erastin 
 
Figure 1.1: Identification and characterization of erastin. A) Structure of 
erastin. B) Dose response of four progressively transformed but otherwise 
isogenic fibroblast lines to erastin. Cell lines are as follows: BJ/TERT (BJeH), 
BJ/TERT/LT/ST (BJeHLT), BJ/TERT/p53DD/CDK4R24C/cyclinD1/ST/RASV12 
(BJ(DRD)), BJ/TERT/LT/ST/RASV12 (BJeLR). C) Light microscopy image of 
BJeLR cells treated for 24 hours with DMSO or erastin (4.6 "M). D) Erastin-
induced death is prevented by iron chelators (deferoxamine, DFO, 100 "M), MEK 
inhibition (U0126, 13 "M), and antioxidants (butylated hydroxyanisole, BHA, 15 
"M). BJeLR cells were co-treated with an inhibitor and 10 "M erastin for 24 
hours. E) Silencing of VDAC3 rescues HT-1080 fibrosarcoma cells from erastin-
induced death.  
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Erastin induces VDAC-dependent ferroptosis 
Several interesting features of erastin-induced death were observed in 
previous studies. Erastin-induced death takes place with generation of reactive 
oxygen species and is suppressed by co-treatment of cells with antioxidants such 
as vitamin E and butylated hydroxyanisole (Figure 1.1D) (Yagoda, von 
Rechenberg et al. 2007). Further studies on erastin also revealed that the activity 
of erastin (as well as RSL3 and RSL5) is dependent on labile iron. Iron chelators 
prevent erastin-induced death, and the transformed cells with increased erastin-
sensitivity have higher levels of intracellular iron compared to non-transformed 
controls (Yang and Stockwell 2008). Increased labile iron could contribute to 
oxidative stress in erastin-induced death by promoting Fenton chemistry.  
The mitochondrial voltage-dependent anion channel-2 and -3 (VDAC2 and 
VDAC3) proteins were identified by affinity pull-down as targets of erastin and 
represent a novel class of proteins that are involved in oncogene-selective cell 
death (Yagoda, von Rechenberg et al. 2007). The VDACs are found in the 
mitochondrial outer membrane where they mediate the flux of small ions and 
metabolites (Colombini 2004). Erastin appears to act through a gain-of-function 
involving VDAC2 and VDAC3, as silencing of VDAC2 and 3 by shRNA prevents 
erastin-induced death. One hypothesis is that erastin acts to perturb VDAC2,3 
channel function leading to mitochondrial dysfunction and iron-dependent 
oxidative stress. As such, erastin-induced death may be a newly characterized 
form of cell death to which cancer cells show increased susceptibility.  We have 
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termed this iron-dependent, oxidative cell death induced by erastin ferroptosis 
and set out to better understand the cell death mechanism. 
 
Reactive oxygen species in ferroptosis  
To better understand the mechanism of ferroptotic cell death, we are 
interested in the role of reactive oxygen species (ROS) observed during 
ferroptosis (Yagoda, von Rechenberg et al. 2007). ROS are molecules that either 
contain or have the capacity to generate oxygen with an unpaired electron. 
These compounds include include superoxide (O2-), hydrogen peroxide (H2O2), 
hydroxyl radical (.OH), and a related class of reactive nitrogen species derived 
from reaction of nitric oxide (NO) with oxygen or superoxide (Winterbourn 2008).  
ROS are implicated in many forms of cell death, including apoptosis (Chang, Cho 
et al. 2004). ROS are also noteworthy in diverse types of non-apoptotic cell 
death. Exogenous ROS can provoke substantial DNA damage, leading to PARP 
activation, mitochondrial AIF release, and caspase-independent cell death (Yu, 
Wang et al. 2002). The natural killer cell (NK cell) serine protease granzyme A 
mediates caspase-independent cell death that requires superoxide production 
from a malfunctioning electron transport chain (Martinvalet, Zhu et al. 2005; 
Martinvalet, Dykxhoorn et al. 2008). In murine fibrosarcoma cells, TNF-! induced 
necrosis requires superoxide production by NADPH oxidase-1 (Kim, Morgan et 
al. 2007; Berghe, Vanlangenakker et al. 2010).  
Tumor cells frequently have higher levels of endogenous ROS and ROS-
related modifications than healthy counterparts, suggesting that oxidative stress 
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is important in development and progression of cancer (Toyokuni, Okamoto et al. 
1995; Petros, Baumann et al. 2005; Trachootham, Zhou et al. 2006). For 
example, ROS-mediated modest DNA damage can promote DNA mutations and 
the genomic instability observed in many tumors. To persist and thrive in the 
setting of increased ROS, transformed cells often increase antioxidant responses 
(Schumacker 2006; Yoo, Xu et al. 2006). It has been suggested that since tumor 
cells have altered redox homeostasis in comparison to healthy cells, modulating 
ROS or antioxidant levels should be a useful therapeutic mechanism to 
selectively eliminate cancer cells (Trachootham, Alexandre et al. 2009). The 
ROS generated during ferroptosis likely represent an important aspect of the 
tumor cell-selective lethality. To better characterize the molecular events leading 
to ferroptosis, it is important to understand how ROS are generated and what 
role(s) ROS may play in the cell death process.  
 
A more complete characterization of ferroptosis  
 The aim of this thesis is to better define the mechanism of ferroptosis in 
human cancer cells. In Chapter Two, I characterize ferroptosis with respect to 
established cell death phenotypes. I find that ferroptosis is a newly-described 
form of mammalian cell death, distinct not only from apoptosis, but also from 
autophagic cell death, accidental necrosis, and various forms of programmed 
necrosis. In Chapter Three, I identify NADPH oxidase-1 as a source of ROS in 
ferroptosis. Tumor cell-derived NADPH production is necessary for ferroptosis 
and suggests a basis for cancer cell selectivity of ferroptosis.  In Chapter 4, I 
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describe studies to better understand the interaction of erastin with its targets, 
the VDAC2,3 proteins and the role of the erastin-VDAC complex in ferroptosis. 
This work also defines regions of the erastin scaffold required for ferroptosis and 
regions that may be modified to improve erastin’s pharmacologic properties as a 
potential anti-tumor agent. Finally, Chapter 5 offers perspectives on the role of 
ferroptosis as a new form of cell death, discusses the relevance of ferroptosis in 
cancer biology, and suggests directions for future studies. 
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Chapter 21: Ferroptosis is Distinct from Apoptosis, 
Autophagic Cell Death, and Necrosis 
 
Introduction 
Multicellular organisms rely on proper control of cell death in development 
and maintenance of health (Hotchkiss, Strasser et al. 2009). In humans, 
disrupted cell death pathways result in diseases such as cancer or 
hyperproliferative blood disorders, while pathologic cell death contributes to 
many neurodegenerative disorders. To more effectively treat these diseases, it is 
important to thoroughly understand regulation of cell viability in both healthy and 
diseased cells.  
 Classically cell death phenotypes have been defined morphologically. The 
three major forms of cell death are apoptosis, autophagic cell death, and 
necrosis (Kerr, Wyllie et al. 1972; Clarke 1990; Galluzzi, Maiuri et al. 2007). 
Apoptosis occurs with chromatin condensation, cellular shrinkage, and 
membrane blebbing. The plasma membrane remains intact until late in the 
apoptotic process. During apoptosis, the cell activates an energy-dependent 
series of biochemical events that lead to degradation of internal cellular 
                                            
1 The following chapter is adapted from a manuscript in preparation: Dixon SJ*, 
Lemberg KM*, Zaitsev E, Yang WS, DiPietrantonio KM, and BR Stockwell. 
Ferroptosis: A Novel Form of Iron-Dependent Oxidative Cell Death. I primarily 
present data from experiments I had a direct role in designing, performing, and/or 
analyzing. Kristina DiPietrantonio, a former technician, assisted with experiments 
presented in Figure 2.4-- Bax-/-;Bak-/- MEF testing (2.4A) and western blotting 
(2.4B,D). Dr. Scott Dixon performed the JC-1 flow cytometry studies presented in 
2.4E. Dr. Wan Seok Yang performed the RIPK1 knockdown and qPCR (2.4F). 
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components by the caspase family of proteases (Yuan, Shaham et al. 1993; Liu, 
Kim et al. 1996; Galluzzi, Maiuri et al. 2007). Debris is packaged and marked for 
non-inflammatory engulfment by phagocytes. Autophagic cell death refers to cell 
death that takes place with extensive cytoplasmic vacuolization as cytoplasmic 
contents are engulfed by double-membrane autophagosomes and recycled in the 
lysosome (Clarke 1990; Klionsky and Emr 2000). In mammalian cells nutrient 
and growth factor availability regulates autophagy through mTOR kinase (Lum, 
DeBerardinis et al. 2005). When autophagy persists for too long, cells may die of 
nutrient deprivation. There exists some debate in the cell death community as to 
whether autophagy is an independent mode of death or rather a pro-survival 
process sometimes observed prior to caspase-dependent apoptosis or 
bioenergetic failure and necrosis (Edinger and Thompson 2004; Degenhardt, 
Mathew et al. 2006). Necrosis may be triggered by severe cellular stress 
resulting in bioenergetic collapse and early disruption of the plasma membrane. 
These events lead to cytoplasmic and organelle swelling with eventual spilling of 
cellular components into the local environment, thus inciting an organism’s 
inflammatory response (Zong and Thompson 2006). In recent years a number of 
other cell death processes have been described. Some of these, such as 
necroptosis and caspase-independent death, appear to be gradations between 
apoptosis and necrosis, while other processes have elucidated novel events or 
functions of proteins participating in execution of cell death (Joza, Susin et al. 
2001; Abraham and Shaham 2004; Degterev, Huang et al. 2005; Overholtzer, 
Mailleux et al. 2007; Martinvalet, Dykxhoorn et al. 2008). 
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Tumor cells frequently acquire a series of genetic changes rendering them 
resistant to apoptosis (Hanahan and Weinberg 2000); therefore it is of great 
interest to discover new agents that induce non-apoptotic cell death in cancer 
cells. Several years ago the Stockwell lab isolated the small molecule erastin in a 
chemical genetic screen for selective cell growth inhibitors of oncogenic RAS-
expressing cancer cells (Dolma, Lessnick et al. 2003). The RAS oncogenes 
encode small GTPases that are mutated in approximately 25% of human tumors 
(Downward 2003). Erastin evoked particular interest because it was evident that 
erastin-induced death was distinct from apoptosis. Erastin-treated cells do not 
undergo morphologic changes observed in apoptosis such as chromatin 
margination, nuclear fragmentation, or plasma membrane blebbing (Dolma, 
Lessnick et al. 2003). From a functional standpoint, the primary distinguishing 
feature of classical apoptosis is activation of the caspases. Erastin-induced death 
shows no evidence of activation of effector caspase 3 or 7 by western blotting or 
fluorogenic substrate assays (Yagoda, von Rechenberg et al. 2007), K. Shimada 
and B.R.S. unpublished), nor is cell death prevented by pan-caspase inhibitors. 
Caspase substrates, such as PARP-1, are not cleaved during erastin-induced 
death (Yagoda, von Rechenberg et al. 2007). 
Additional studies on the activity of erastin (and 2 related, structurally-
distinct RAS-selective lethal compounds identified in the lab) have revealed that 
erastin’s activity is dependent on the intracellular iron pool and involves 
generation of reactive oxygen species (Yang and Stockwell 2008). The 
mitochondrial voltage-dependent anion channel-2 and -3 (VDAC2 and VDAC3) 
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proteins were identified by affinity pull-down as targets of erastin and represent a 
novel class of proteins that are involved in cancer cell death (Yagoda, von 
Rechenberg et al. 2007). We have termed this iron-dependent, oxidative cell 
death induced by erastin ferroptosis and set out to better understand the cell 
death mechanism. 
 The first goal of this thesis work is to better understand the cell death 
phenotype triggered by erastin. Although we had substantial evidence suggesting 
that erastin-induced ferroptosis is distinct from apoptosis, we were motivated to 
establish the relationship, if any, between erastin-induced ferroptosis and other 
forms of non-apoptotic cell death, particularly autophagic cell death and necrosis.  
For example, were erastin shown to trigger a known form of non-apoptotic death, 
this would immediately make erastin an important new tool compound to study a 
known cell death phenotype.  Conversely, if it were demonstrated that ferroptosis 
is unique, it would be very interesting to characterize this phenotype further as it 
could reveal novel information about pathways regulating cell viability. 
Furthermore it would suggest that ferroptosis, as a mode of non-apoptotic death, 
could be a useful form of cell death to trigger in cancer cells that have evolved 
resistance to apoptosis. Here, using a combination of assays, we show that 
erastin-induced ferroptosis is distinct from apoptosis, autophagy, and necrosis on 






Our first goal was to evaluate the relationship between VDAC2,3-
dependent ferroptosis (hereafter referred to as simply ferroptosis) and other cell 
death phenotypes.  Cell death phenotypes can be distinguished on the basis of 
various morphological, biochemical and genetic criteria (Kroemer, Galluzzi et al. 
2009).  We first focused on the morphology of cells undergoing ferroptosis.  As a 
model we used erastin-sensitive human foreskin fibroblasts engineered to 
express telomerase (TERT), large and small T oncoproteins (LT, ST) and an 
oncogenic HRAS allele (BJ/TERT/LT/ST/RASV12, hereafter referred to as BJeLR) 
(Hahn, Counter et al. 1999).  BJeLR cells were treated with prototypic inducers of 
ferroptosis (erastin), apoptosis (staurosporine, STS), classic necrosis (hydrogen 
peroxide, H2O2) or autophagy (rapamycin) and examined at the ultrastructural 
level using transmission electron microscopy. Consistent with previous 
observations of mitochondrial involvement in ferroptosis (Yagoda, von 
Rechenberg et al. 2007), the primary distinguishing feature of erastin-treated 
cells was disruption of the mitochondrial ultrastructure: mitochondria appear 
smaller and have increased membrane density (Figure 2.1 and 2.2). These 
features were not observed in cells undergoing STS-induced apoptosis or 
rapamycin-induced autophagy, while mitochondria in cells undergoing H2O2-
induced necrosis were swollen and had more diffuse inner membranes.  Erastin-
treated cells did not exhibit nuclear condensation, cytoplasmic/organelle swelling 
or plasma membrane rupture, or the formation of double-membraned vacuoles—
characteristic morphologic features associated with apoptosis, necrosis and 
autophagy, respectively (Table 2.1; Figure 2.1). These distinguishing features 
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were observed in the respective control treatments, as expected (Table 2.1; 




Figure 2.1: Morphology of ferroptosis compared to other cell death 
phenotypes 
 
Figure 2.1: Morphology of ferroptosis compared to other cell death 
phenotypes. Morphology of cells dying in response to erastin is distinct from 
inducers of apoptosis, necrosis, and autophagic cell death. Transmission 
electron microscopy of BJ/TERT/LT/ST/RASV12 cells treated with erastin and 
established cell death inducers. Vehicle (DMSO), erastin (37 "M; 10 hr), 
staurosporine (0.75 "M; 6-8 hr), hydrogen peroxide (16 mM; 1 hr), or rapamycin 
(100 nM; 24 hr). Arrowheads indicate the following features: dysmorphic 
mitochondria (white arrowheads; erastin), chromatin condensation along nuclear 
membrane (double white arrowheads; STS), cytoplasmic swelling and disruption 
of plasma membrane (black arrowheads; hydrogen peroxide); swollen 
mitochondria (double black arrowheads; hydrogen peroxide), double-membrane 
enclosed compartments (black arrow; rapamycin).   
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Figure 2.2: Detailed comparison of morphology of BJeLR cells treated with 
vehicle (DMSO; 10 hours) or erastin (37 "M; 10 hours). Highlighted regions in the 
low magnification images are expanded to higher magnification. Black arrows 
indicate mitochondria in control cell population; white arrows indicate 








Table 2.1: Evaluation of cell death features by transmission electron 
microscopy.  BJeLR cells were treated with different inducers of cell death: 
DMSO, erastin (37 "M; 10hr), staurosporine (0.75 "M; 6-8hr), hydrogen peroxide 
(16 mM; 1hr), or rapamycin (100 nM; 24h), then fixed and examined by TEM. (+) 
feature observed; (-) feature not observed. 
Treatment DMSO Erastin  Staurosporine H2O2 Rapamycin 
n (# cells evaluated) 10 13 8 3 4 
Disruption of plasma membrane - - - + - 
Chromatin condensation - - + + - 
Cytoplasmic vesiculation - - - + - 
Mitochondrial swelling - - - + - 
Disruption of cristae - + - + - 
ER-ribosome associations + + + - + 




To assess functional parameters associated with ferroptosis, we next 
examined a panel of small molecule cell death inhibitors for the ability to prevent 
ferroptosis. Established inhibitors of caspases, calpain/cathepsin proteases, 
necroptosis, the mitochondrial permeability transition pore, and autophagosomes 
were tested for the ability to suppress erastin-induced ferroptosis in three 
different erastin-sensitive cell lines (HT-1080 fibrosarcoma cells, Calu-1 lung 
carcinoma cells, and BJeLR cells). Four small molecules previously known to 
inhibit ferroptosis in BJeLR cells were included as positive controls: the iron 
chelator deferoxamine (DFO), the antioxidant Trolox (Tlx), the protein synthesis 
inhibitor cycloheximide (CycH), and the MEK inhibitor U0126 (Yagoda, von 
Rechenberg et al. 2007; Yang and Stockwell 2008) (Table 2.2). We found that at 
the maximum concentrations evaluated DFO, Tlx, and U0126 inhibited erastin-
induced ferroptosis by over 55% in all three cell lines, while CycH was less 
effective and also somewhat toxic to control cells in the absence of erastin 
(Figure 2.3). Conversely, the highest doses of the other cell death inhibitors were 
ineffective at preventing ferroptosis by more than 20% (Figure 2.3).   
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Figure 2.3: Screen for small molecule suppressors of ferroptosis. Heatmap 
shows the difference in percent viability (# % viability) between cells co-treated 
with erastin and inhibitor and cells treated with erastin only. Grey squares 
indicate concentrations of inhibitor alone that reduced alamar blue fluorescence 
to below 50% of the maximum signal, which we excluded from the analysis. HT-
1080 (H), Calu-1 (C), and BJ/TERT/LT/ST/RASV12 (R) cells were co-treated with 
10 "M erastin and a four point, five-fold dilution series of the indicated small 
molecule inhibitors for 24 hours. Viability was assessed using alamar blue 
fluorescence. Inhibitor abbreviations and the maximum concentration shown in 
the figure are given in Table 2.2. 
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Table 2.2: Inhibitors used to identify suppressors of ferroptosis (Figure 2.3). 
Abbrev. Full name Activity 
High conc. 









(Zhu, Fearnhead et al. 
1995) 
Nec-1 necrostatin-1 
RIP kinase 1 
inhibitor 
19.3 
(Degterev, Hitomi et al. 
2008) 





Harding et al. 1984; 





calpain inhibitor 40.0 








calpain inhibitor 400.0 
(McGowan, Becker et al. 
1989) 










of class 3 PI3K 
6250.0 
(Seglen and Gordon 
1982; Petiot, Ogier-







(Seglen, Grinde et al. 
1979; Paglin, Hollister et 
al. 2001) 
DFO deferoxamine iron chelator 400.0 
(Richardson and Ponka 
1998) 
Tlx Trolox antioxidant 319.6 (Buettner 1993) 
U0126 U0126 MEK inhibitor 52.4 





5.6 (Siegel and Sisler 1963) 
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* Maximum concentrations of inhibitors used were chosen based on literature 





Genetic reagents and biochemical assays for mediators of apoptotic, 
necrotic and autophagic cell death further distinguished ferroptosis. Ferroptosis is 
unaffected by gene deletion of the pro-apoptotic proteins BAX and BAK (Figure 
2.4A), which promote mitochondrial outer membrane permeabilization (MOMP) 
and cell death, even in the absence of effector caspase activation (Xiang, Chao 
et al. 1996; Wei, Zong et al. 2001). A marker of autophagy, the autophagosome-
associated form of Light Chain 3 protein, does not increase during ferroptosis 
(Figure 2.4B) (Kabeya, Mizushima et al. 2000). Ferroptosis occurs independently 
of the cyclophilin D-dependent mitochondrial permeability transition pore (mPTP) 
(Figure 2.4C) and without loss of mitochondrial transmembrane potential (Figure 
2.4D) (Baines, Kaiser et al. 2005). Severe DNA damage, measured by 
phosphorylation of p53-serine 15, does not occur during ferroptosis (Figure 2.4E) 
(Shieh, Ikeda et al. 1997). Finally, expression of RIP1 kinase, a driver of 
necroptosis, does not affect ferroptosis (Figure 2.4F) (Degterev, Hitomi et al. 
2008). These data substantiate the results obtained by TEM and the small 
molecule suppressor screen highlighting the unique aspects of ferroptosis in 
relation to other major forms of cell death. 
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Figure 2.4: Genetic and biochemical assays for indications of apoptosis, 




Figure 2.4 (continued) 
 
 
Figure 2.4: Genetic and biochemical assays for indications of apoptosis, 
autophagy, and necrosis in erastin-induced ferroptosis. (A) Role of pro-
apoptotic Bcl-2 family members BAX and BAK in ferroptosis. (Left panel) Wild-
type (WT) and Bax-/- Bak-/- mouse embryonic fibroblasts (MEFs) were treated 
with a dilution series of erastin and viability was assessed using alamar blue 
fluorescence. (Right panel) Staurosporine (STS) treatment of WT and Bax-/- Bak-
/- MEFs is shown as a control. (B) Western blot of light chain 3 (LC3) protein 
during erastin-induced death. The autophagosome-associated LC3-ii form does 
not accumulate over a time course of erastin treatment in 
BJ/TERT/LT/ST/RASV12 cells.  Treatment using the lysosomotropic agent 
chloroquine, which leads to accumulation of LC3-ii, is shown as a positive 
control. Cells were treated with vehicle only (D), erastin (Era; 37 "M) for 2, 4, 6, 
and 8 hours, or with chloroquine (Chq; 50 "M) for 6 hours and 20 hours. (C) 
Silencing of PPIF (gene for cyclophilin D) does not rescue HT-1080 cells from 
erastin-induced death. (Left panel) Cells were infected with lentivirus expressing 
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shRNAs targeting PPIF for 48 hours, puromycin-selected for 24 hours, and 
treated with erastin for 24 hours. Viability was assessed by alamar blue 
fluorescence. (Right panel) In parallel mRNA levels of PPIF were assessed by 
quantitative RT-PCR. (D) Cells maintain mitochondrial membrane potential 
during erastin-induced death. HT-1080 cells were treated with DMSO, erastin, or 
the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) 
as a positive control for times indicated. Cells were incubated with the 
mitochondrial membrane potential sensitive dye JC-1 and fluorescence was 
measured using flow cytometry. In comparison to CCCP, erastin-treated cells do 
not show a loss of JC-1 red fluorescence indicative of loss of membrane 
potential. (E) Erastin treatment does not lead to severe DNA damage as 
monitored by phosphorylation of p53 Ser15. In contrast, cells treated with the 
DNA intercalating agent doxorubicin demonstrate an increase in phosphorylation 
at p53 Ser15. BJ/TERT/LT/ST/RASV12 cells were treated with no treatment (-), 
erastin (Era; 37 "M; 2, 4, 6, or 8 hrs), or doxorubicin (Dxr; 1.8 "M; 0.5, 2, or 6 
hrs). Tubulin was used as a loading control. (F) Silencing of receptor-interacting 
kinase 1 (RIPK1) does not rescue HT-1080 cells from erastin-induced death. 
(Left panel) Cells were infected with lentiviruses expressing either a non-
targeting shRNA or RIPK1-targeting shRNAs. After 5 days of shRNA expression, 
each cell line was treated with erastin to examine any rescuing effect of RIPK1-
targeting shRNAs on erastin-induced death. Alamar blue dye was used for cell 
viability assessment. (Right panel) In parallel, quantitative RT-PCR determined 




As another means to explore the biochemical uniqueness of ferroptosis, 
we examined the intracellular levels of ATP.  During apoptosis, ATP levels are 
maintained until late in the death process, while immediate and rapid ATP 
depletion, due to loss of plasma membrane integrity, is a distinguishing hallmark 
of classic necrosis (Zong and Thompson 2006).  Using a luciferase-based assay, 
we observed that cellular ATP levels were not only maintained, but substantially 
increased in erastin-treated BJeLR (and HT-1080) cells undergoing ferroptosis 
(Figure 2.5A).  No change in ATP levels was observed in cells treated with 
inducers of apoptosis (STS) or autophagy (rapamycin), while treatment with an 
inducer of necrosis (H2O2) resulted in the complete loss of intracellular ATP 
(Figure 2.5A).  The observed increase in ATP in erastin-treated cells was 
prevented by co-treatment with known small molecule inhibitors of ferroptosis 
(DFO, U0126 and the antioxidant BHA) (Figure 2.5B) and independent of the 
method used to assess cell viability (Figure 2.5C).  
To gain insight into how the excess ATP was formed, we co-treated HT-
1080 cells with erastin and either the hexokinase inhibitor 2-deoxyglucose (2-DG) 
or inhibitors of oxidative phosphorylation (rotenone, antimycin A, and oligomycin) 
(Figure 2.5D). Inhibitors of oxidative phosphorylation did little to prevent the 
increase in ATP upon erastin-treatment. However both the basal and erastin-
induced increase in ATP levels were inhibited by co-treatment with 2-DG (Figure 
2.5E). Ferroptotic death was also attenuated by 2-DG as well as a second 
glycolytic inhibitor, sodium fluoride (Figure 2.5F and not shown). These data link 
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the increase in ATP levels and cell death to a process upstream or independent 








Figure 2.5: ATP Levels Increase During Induction of Ferroptosis. (A) ATP 
levels increase during erastin-induced ferroptosis, in contrast to apoptosis, 
necrosis, and autophagy. Bioluminescence measurement of ATP levels in 
BJ/TERT/LT/ST/RASV12 cells treated with vehicle (DMSO), staurosporine (0.5 
"M, 6hr), hydrogen peroxide (16 mM; 2hr), erastin (37 "M, 10hr). Cell viability 
was determined in parallel using the dye Alamar blue. (B) ATP level increase is 
prevented in cells co-treated with inhibitors of ferroptosis. HT-1080 cells were co-
treated with DMSO or erastin (9.1 "M) and a suppressor of ferroptosis: 
deferoxamine (DFO; 100 "M), butylated hydroxyanisole (BHA; 15 "M), and 
U0126 (MEK inhibitor; 10 "M) for 8 hours. (C) ATP levels increase during erastin-
induced death in HT-1080 cells. HT-1080 cells treated with DMSO or erastin (9.1 
"M) for 8 hours. Viability was determined in parallel by Trypan Blue dye 
exclusion assay.  (D) Schematic representing ATP production by glycolysis or 
oxidative phosphorylation. Inhibitors used in subsequent panels are shown in 
purple. E) ATP increase is prevented by co-treatment with 2-deoxy-D-glucose (2-
DG; 50 mM) but not with inhibitors of oxidative phosphorylation: rotenone (Rote; 
150 nM), antimycin A (Anti; 10 "M), or oligomycin (Olig; 1 "M). HT-1080 cells 
were co-treated with DMSO or erastin (9.1 "M) and the indicated inhibitors for 6 
hours. (F) 2-DG rescues HT-1080 cells from ferroptosis. HT-1080 cells were co-
treated with 2-DG and DMSO or erastin (4.6 "M). Viability was assessed by 






Based on the studies of cell morphology, chemical suppressors, functional 
assays, and bioenergetics presented here, we have shown that erastin-induced 
ferroptosis is distinct from apoptosis, autophagic cell death, necrosis, and 
necroptosis. Across multiple cell types ferroptosis is an active, iron-dependent 
oxidative cell death. Previous work has shown that ferroptosis is dependent on 
the VDAC2,3 proteins, and a recent shRNA screen examining over 1,000 genes 
has identified eleven additional genes that uniquely modulate ferroptosis (S. 
Dixon and B. Stockwell, unpublished). Collectively these data characterize 
ferroptosis as a newly-described, modulatable form of cell death of great interest 
for further studies. 
While many of the cell death events investigated in the course of these 
studies were found not to occur in ferroptosis, several features were observed 
that seem to be unique to ferroptosis. The electron microscopy studies presented 
here distinguish ferroptosis from staurosporine-induced apoptosis, hydrogen 
peroxide-induced necrosis, and rapamycin-induced autophagy based on cell 
morphology. Following 10 hours of erastin treatment, the ultrastructural studies 
reveal that BJeLR cells appear largely normal, though fewer in number than 
untreated cells. The primary morphologic disturbance during ferroptosis is an 
alteration in mitochondrial size and membrane structure. Mitochondria appear on 
average smaller, less tubular, and with darker-staining membranes. Distinct inner 
membrane foldings (cristae) are disrupted or effaced. Mitochondrial 
fragmentation has been observed following multiple cell death stimuli (Frank, 
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Gaume et al. 2001; Suen, Norris et al. 2008). While quantitative studies on 
fragmentation during ferroptosis were not carried out, the observed average 
mitochondrial size following erastin-treatment was clearly smaller than in the 
STS-treated samples. It is not known whether the fragmentation observed during 
ferroptosis is required for cell death, although in some settings inhibition of 
mitochondrial fission prevents cytochrome c release and apoptosis (Suen, Norris 
et al. 2008). The increasing density of the matrix and loss of cristae were also 
intriguing, as they were not observed following any of the other treatments. 
Several researchers have described a “matrix condensed” state of the 
mitochondria that occurs along with loss of mitochondrial membrane potential 
following pro-apoptotic stimuli or withdrawal of growth factors (Scorrano, Ashiya 
et al. 2002; Gottlieb, Armour et al. 2003). Mitochondria in cells undergoing 
ferroptosis appear condensed but do not experience loss of mitochondrial 
membrane potential (Figure 2.4D). Cotreatment with the uncoupler CCCP, which 
provokes loss of membrane potential also has little effect on ferroptosis (see 
Chapter 3). These mitochondrial morphology changes are consistent with an 
effect of erastin on the VDAC2,3 proteins at the outer membrane, but the precise 
implications of mitochondrial fragmentation and condensation for ferroptosis 
remain to be determined.  
 From a functional standpoint the effect on mitochondria during ferroptosis 
appears to be distinct from both pro-apoptotic MOMP and pro-necrosis mPTP 
formation. VDAC2, a target of erastin, may interact with and sequester pro-
apoptotic BAK (Cheng, Sheiko et al. 2003). However Bax-/- Bak-/- and wild-type 
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MEFs were equally sensitive to ferroptosis, indicating that the effect of erastin on 
VDAC2 and induction of ferroptosis is independent of the VDAC2-BAK 
interaction. Furthermore, erastin does not promote matrix swelling through a 
VDAC-cyclophilin D dependent mitochondrial permeability transition pore 
(Baines, Kaiser et al. 2005). Thus the manner in which erastin-VDAC affects 
mitochondria to induce morphologic changes as well as ferroptosis appears to be 
completely distinct from these characterized processes.  
A distinguishing feature of ferroptosis observed here is the 2-DG-sensitive 
increase in intracellular ATP levels prior to ferroptotic death. Others have 
reported 2-DG-sensitive increases in ATP levels under apoptotic conditions in 
other cell lines (Zamaraeva, Sabirov et al. 2005), suggesting that rises in ATP 
levels may be common. One model accounting for our observations is that the 
erastin/VDAC interaction inhibits mitochondrial oxidative phosphorylation, leading 
to a compensatory up-regulation of ATP production through glycolysis (Wu, 
Neilson et al. 2007). However, this model does not account for the ability of 
various death suppressing compounds that have no effect on glycolysis alone 
(BHA, DFO and U0126) to suppress the rise in ATP levels during ferroptosis.  
Moreover, various metabolic analyses disclose no direct effect of erastin on 
lactate production, an indicator of glycolysis (see Chapter 3 and not shown).  An 
alternative model is that the induction of ferroptosis involves ROS-mediated 
inhibition of a specific ATP-consuming process, resulting in the relative 
accumulation of intracellular ATP.  One possibility is that during ferroptosis a 
specific, ATP-dependent process that would normally respond to the increase in 
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oxidative stress may be prevented from doing so.  In mouse cells deficient for the 
DNA-repair enzyme PARP, for example, exposure to oxidative stress results in 
an increase in ATP (Ha and Snyder 1999), suggesting that this model is 
plausible. Further work will be required to identify the putative ATP-dependent 
process and determine whether it is the excess accumulation of ATP or the 
accumulation of another 2-DG-sensitive metabolite that is crucial for death. 
 
Materials and Methods  
 
Chemicals/Antibodies/Reagents 
Erastin was commercially synthesized as described (Yagoda, von Rechenberg et 
al. 2007). Cycloheximide, puromycin, staurosporine, 6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (Trolox), deferoxamine mesylate, 
necrostatin-1, cyclosporine A, 3-methyladenine, and chloroquine were from 
Sigma. Rapamycin was from Cell Signaling Technologies. z-VAD-fmk was from 
BioMol. ALLN and E64D were from CalBiochem. Bafilomycin A1 and U0126 
were from LC Laboratories. Compounds were diluted in DMSO, ethanol or water 
and typically used within one month of preparation.  
 
Cell Lines/Cell Culture 
BJ/TERT/LT/ST/RASV12 (BJeLR) and matched controls were obtained from 
William Hahn (Harvard University). BJ series cells were grown in DMEM plus 
20% M199 and 15% heat-inactivated FBS.  HT-1080, Calu-1, and 293T cells 
were from American Type Culture Collection (ATCC). Calu-1 cells were grown in 
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McCoy’s 5A media supplemented with 10% fetal bovine serum. HT-1080 cells 
were grown in DMEM High-Glucose media (Gibco) supplemented with 10% fetal 
bovine serum (FBS) and 1% non-essential amino acids (Gibco). 293-Tcells were 
grown in DMEM High-Glucose supplemented with 10% FBS. When used for 
transfections to generate virus, 293-T cells were seeded in the above media 
lacking antibiotics.  293-T viral collection media contained 30% HyClone FBS.   
MEFs (Bax-/-;Bak-/- and wild-type) were a gift from Craig Thompson. MEFs were 
grown in DMEM supplemented with 10% fetal calf serum. All cell lines were 
grown in humidified tissue culture incubators (Thermo Scientific) at 37oC with 5% 
CO2.  All medias were supplemented with penicillin and streptomycin (Gibco).  
 
Transmission Electron Microscopy 
BJ/TERT/LT/ST/RASV12 cells were plated at 100,000 cells/dish in 35 mm tissue 
culture dishes. After 12h cells were treated with vehicle (DMSO; 10 hrs), erastin 
(37 "M; 2, 4, 6, 8, 10 hrs), staurosporine (750 nM; 2, 4, 6, 8, 10 hrs), hydrogen 
peroxide (16 mM; 90 min) or rapamycin (100 nM; 24 hrs). Cells were fixed with 
2.5% glutaraldehyde in 0.1 M Sorenson's buffer (0.1 M H2PO4, 0.1 M HPO4 
(pH 7.2)) for at least 1 h, and then treated with 1% OsO4 in 0.1 M Sorenson's 
buffer for 1 h. Enblock staining used 1% tannic acid. After dehydration through an 
ethanol series, cells were embedded in Lx-112 (Ladd Research Industries) and 
Embed-812 (EMS). Thin sections were cut on an MT-7000 ultramicrotome, 
stained with 1% uranyl acetate and 0.4% lead citrate, and examined under a Jeol 
JEM-1200 EXII electron microscope. Pictures were taken on an ORCA-HR digital 
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camera (Hamamatsu) at 5,000-50,000-fold magnification, and measurements 
were made using the AMT Image Capture Engine. 
 
Cell Death Small Molecule Inhibitor Screen 
Cells (BJ/TERT/LT/ST/RASV12 [BJeLR], HT-1080, and Calu-1) were seeded the 
night before experiment in 384 well black clear bottom plates (Corning) at a 
density of 1000 cells/well using a Beckman Biomek FX Workstation. All inhibitors 
(except 3-methyladenine and chloroquine) were made in DMSO at 250-fold the 
final highest concentration and aliquoted across a 384-well plate (Grenier). A 
five-fold dilution series of each inhibitor in DMSO was made using a multichannel 
pipette. Replicates of this mother plate were stored at -20 C. On the day of the 
experiment, a fresh inhibitor plate was thawed and then diluted twenty-five fold 
into DMEM in a 384-well deep daughter plate (Grenier) using the Biomek. Media 
was removed from cells and replaced with media containing DMSO (0.1%) or 
erastin (10 "M final concentration). Using the Beckman Biomek a 1/10 dilution 
was made from the inhibitor daughter plate into the DMSO- or erastin-containing 
assay plates. For 3-methyladenine and chloroquine, inhibitors were made in 
media at 10-fold the final concentration in the presence of DMSO or 10 uM 
erastin. These solutions were manually pipetted onto cells in 384-well format. 
Assay plates were incubated at 37˚C for 24h. Viability was assessed using 
Alamar blue. Data analysis was done in Excel and the percent change in viability 
of cells in the presence of erastin with a given inhibitor versus erastin alone were 
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computed. These results were used to generate the heatmap in Figure 1B using 
the statistical program R.  
 
Cell viability measurements 
Cell viability was assessed using one of two methods as indicated in individual 
Figures: Alamar blue fluorescence or Trypan Blue dye exclusion. Alamar blue 
(Invitrogen) is a cell-permeant resazurin-based dye that is reduced by 
metabolically active cells to rezorufin, a dye with red fluorescence. Fluorescence 
was measured using a Victor3 platereader with excitation filter at 530 nm and 
emission filter centered on 590 nm. Trypan Blue is a vital dye that is excluded 
from live cells but permeates dead cells. Trypan Blue negative and positive cells 
were counted using an automated cell counter (ViCell, Beckman-Coulter). In 
addition to the staining methods, wherever possible cell morphology was also 
assessed by light microscopy.  
 
Western blotting 
Cells were trypsinized, pelleted, and washed twice in cold PBS. Cells were lysed 
in buffer containing: 50 mM HEPES pH 7.4, 40 mM NaCl, 2 mM EDTA, 0.5% 
Triton-X-100, 1.5 mM sodium orthovanadate, 50 mM NaF, 10 mM sodium 
pyrophosphate, 10 mM sodium ß-glycerophosphate, and protease inhibitor tablet 
(Roche). Unlysed cells and debris were pelleted for 10 min at 10,000 rpm in a 
benchtop microcentrifuge at 4˚C, and the supernatant was removed and mixed 
with 5x SDS loading buffer. Loading of samples was normalized by either cell 
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count or protein quantitation colorimetric assay (BioRad). Samples were 
separated by SDS-polyacrylamide gel electrophoresis. Western transfer was 
performed using the iBlot system (Invitrogen). Membrane was blocked for 1 hour 
in Licor Odyssey Blocking Buffer and incubated in primary antibody overnight at 
4˚C. Following 3x10 minute washes in Tris-buffered saline (pH 7.4) with 1% 
Tween-20, membrane was incubated with secondary antibodies for 30 minutes in 
the dark. The membrane was washed again in TBST for 3x10 minutes with 
protection from light and scanned using the Licor Odyssey Imaging System. 
Antibodies used were as follows: Tubulin (Santa Cruz; sc-32293), LC-3B (Cell 
Signaling, 2775), p53-Ser15 (Cell Signaling).Secondary antibodies were IR dye 
800CW goat anti-rabbit IgG and IR dye 700CW goat anti-mouse IgG (LICOR). 
 
Analysis of mitochondrial transmembrane potential ("#m) 
Cells were seeded in 6-well dishes at a density of 200,000 cells/well the day 
before analysis.  On the day of analysis cells were treated with test compounds 
then harvested by trypsinization and washed once in PBS.  Cells were then 
resuspended in 0.5 mL PBS incubated containing 2 µM (final) 5,5',6,6'-
tetrachloro-1,1',3,3'-tetra-thylbenzimidazole carbocyanide iodide (JC-1, 
Invitrogen) and incubated in the dark for 20 minutes in a 37oC incubator.  Cell 
were pelleted once again, resuspended in 0.5 mL PBS and analyzed immediately 
by flow cytometry as described above using the collection filters for the green 




Bioluminescence studies of ATP levels 
ATP levels were evaluated using the ApoSENSOR ATP Assay Kit (Biovision) 
according to the manufacturer’s instructions. Briefly 2000 HT-1080 or 
BJ/TERT/LT/ST/RASV12 cells were seeded in 96-well white bottom plates 
(Falcon). Cells were treated 12 hours later with compound for times indicated. 
Prior to luminescence measurement, media was removed and cells were lysed 
and incubated with ATP Monitoring Enzyme. Luminescence was measured using 
a Victor3 platereader equipped with an infrared emission filter every 30s for 10 
minutes. Typically the first reading was used for data analysis. Parallel cell 
culture treatments were performed in 96-well clear bottom plates or 6 well dishes 
and cell viability was determined using the viability dyes alamar blue or trypan 
blue, respectively. 
 
Lentivirus production and shRNA knockdown in 384-well or 6-well format 
Lentivirus expressing shRNAs against target genes was produced in HEK293T 
cells using a three-plasmid system. 293T cells were seeded at 50% confluence in 
either 10 cm or 6-well culture dishes in antibiotic-free media. The following day 
cells were cotransfected with the viral packaging plasmid (p-#8.9), the viral 
envelope plasmid (p-VSVG), and the shRNA-encoding plasmid (pLKO.1) using 
FuGENE-6. Transfected cells were incubated for thirty-six hours at 37˚C, 5% 
CO2, at which point the media was replaced with viral collection media (DMEM 
supplemented with 30% HyClone FCS and penicillin/streptomycin). Three 
collections and replacements of viral collection media were made over 36 hours, 
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and the viral supernatant was subsequently spun down to pellet any unattached 
cells/debris and aliquoted. Frozen aliquots were stored at -80˚C. 
 
shRNA Knockdown 
For 384-well experiments (cell viability measurements in response to lethal 
compounds) cells were infected with 2 µL of unconcentrated viral stock per well.  
For 6-well dish experiments (RT-qPCR, flow cytometry, microscopic imaging) 
cells were infected with 150 µL of virus.  In both cases, following virus addition, 
cell were spun for 1.5 hours at 2,250 rpm at 37oC.  Two days after infection cells 
were treated with 1.5 µg/mL puromycin.  Assays (i.e. drug treatment, flow 
cytometry, mRNA harvesting) were performed starting 24 hours later. 
 
RT-qPCR 
RNA was extracted using the QIAshredder and Qiagen RNeasy Mini kits 
(Qiagen) according to the manufacturers.  2 µg total RNA for each sample was 
used as input for each reverse transcription reaction, performed using the 
TaqMan RT kit (Applied Biosystems). Quantitative PCR reactions were 
performed using the Power SYBR green PCR Master mix (Applied Biosystems).  
Triplicate samples per condition were analyzed on an Applied Biosystems 7300 
qPCR instrument using absolute quantification settings.  Differences in mRNA 
levels compared to an HPRT1 internal reference control were computed between 
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Chapter 32: NADPH Oxidase-1 Derived ROS are 
Necessary for Ferroptosis 
 
Introduction 
 Reactive oxygen species (ROS) are molecules that either contain or have 
the capacity to generate oxygen with an unpaired electron. These compounds 
include include superoxide (O2-), hydrogen peroxide (H2O2), hydroxyl radical 
(.OH), and a related class of reactive nitrogen species derived from reaction of 
nitric oxide (NO) with oxygen or superoxide (Winterbourn 2008). In multicellular 
organisms, ROS play important roles in enzyme activity, cell signaling, 
transcription regulation, and host defense (Sundaresan, Yu et al. 1995; Hirota, 
Murata et al. 1999; Nordberg and Arner 2001). However, excessive levels of 
ROS, particularly the highly reactive hydroxyl radical, may cause widespread 
damage by modifying proteins, lipids, and DNA. Cells generate ROS as a 
consequence of exposure to heavy metals or metabolism of xenobiotics (Ding 
and Shi 2002; Winterbourn 2008) or as a product of normal physiology. The 
mitochondrial electron transport chain is a significant source of superoxide 
following incomplete reduction of molecular oxygen to water. Many flavin-
containing enzymes also generate ROS as a product of their activity. Examples 
include the NADPH oxidases, xanthine oxidase, ER protein folding machinery, 
                                            
2 The following chapter is adapted from a manuscript in preparation: Dixon SJ*, 
Lemberg KM*, Zaitsev E, Yang WS, DiPietrantonio KM, and BR Stockwell. 
Ferroptosis: A Novel Form of Iron-Dependent Oxidative Cell Death. The 
experiments in figures 3.2 and 3.5 were contributed by Dr. Scott Dixon.  
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and peroxisomal proteins (Nelson and Cox 2000; Dansen and Wirtz 2001; 
Harding, Zhang et al. 2003). To balance the need for ROS in cell physiology with 
prevention of non-specific oxidations of biomolecules, cells maintain antioxidant 
defenses consisting of both enzymatic (catalase, SOD, glutathione peroxidase) 
and non-enzymatic (glutathione, ascorbate) means to detoxify ROS (Nordberg 
and Arner 2001). 
Superoxide itself may oxidize iron sulfur clusters but is not membrane 
permeable and does not cause widespread non-specific damage.  It undergoes 
spontaneous or enzyme-catalyzed dismutation to hydrogen peroxide (McCord 
and Fridovich 1969). Hydrogen peroxide can oxidize cysteine thiol groups in 
active sites of proteins and serve as a source of hydroxyl radical following 
transition-metal catalyzed Fenton and Haber-Weiss reactions (Figure 3.1) 
(D'Autreaux and Toledano 2007). Furthermore, a compromised cellular 
antioxidant system may disable the cell’s ability to buffer normal levels of ROS 
(Huang, Feng et al. 2000), and reactions with transition metals or biomolecules 
can then amplify oxidative stress in the cell (Marnett, Riggins et al. 2003). 
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Figure 3.1: Schematic of major forms of cellular ROS 
 
Figure 3.1: Schematic of major forms of cellular ROS. Iron-catalyzed Fenton 




ROS are implicated in cellular dysfunction leading to apoptotic cell death 
(Chang, Cho et al. 2004). In addition, ROS are also noteworthy in diverse types 
of non-apoptotic cell death. Exogenous ROS can provoke substantial DNA 
damage, leading to PARP activation, mitochondrial AIF release, and caspase-
independent cell death (Yu, Wang et al. 2002). The natural killer cell serine 
protease Granzyme A mediates caspase-independent cell death that requires 
superoxide production from a malfunctioning electron transport chain 
(Martinvalet, Zhu et al. 2005; Martinvalet, Dykxhoorn et al. 2008). In murine 
fibrosarcoma cells, TNF-! induced necrosis requires superoxide production by 
NADPH oxidase-1 (Kim, Morgan et al. 2007; Berghe, Vanlangenakker et al. 
2010). ROS generation is also implicated in ferroptosis, and ferroptosis is 
prevented by antioxidants (Yagoda, von Rechenberg et al. 2007). 
Tumor cells frequently have higher levels of endogenous ROS and ROS-
related modifications than healthy counterparts, suggesting a possible role for 
oxidative stress in the development and progression of cancer (Toyokuni, 
Okamoto et al. 1995; Petros, Baumann et al. 2005; Trachootham, Zhou et al. 
2006). For example, ROS-mediated modest DNA damage can promote DNA 
mutations and the genomic instability observed in many tumors. To persist and 
thrive in the setting of increased ROS, transformed cells often increase 
antioxidant responses (Schumacker 2006; Yoo, Xu et al. 2006). It has been 
suggested that since tumor cells have altered redox homeostasis in comparison 
to healthy cells, modulating ROS or antioxidant levels should be a useful 
therapeutic mechanism to selectively eliminate cancer cells (Trachootham, 
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Alexandre et al. 2009). While some currently used cytotoxic chemotherapeutics 
such as bleomycin and daunorubicin invoke ROS in mediating DNA damage 
(Brunton, Lazo et al. 2005), a better understanding of redox homeostasis in 
tumor cells should allow new therapies to target additional ROS-related 
processes.  
Ferroptosis involves generation of ROS and is prevented by antioxidants 
(Yagoda, von Rechenberg et al. 2007). To better characterize the molecular 
events leading to ferroptosis we were interested in defining a source of death-
inducing ROS during ferroptosis. We hypothesized that labile iron could play a 
role in ROS propagation by Fenton and Haber-Weiss reactions leading to cell 
damage and death. However, we wanted to localize a source of initial ROS in 
order to understand erastin’s mechanism of action in cells. In order to do this, we 
focused on both mitochondrial and non-mitochondrial sources of ROS. We found 
that inhibition of NADPH oxidases—specifically NOX1—but not the mitochondrial 
ETC, prevents ferroptosis in tumor cells. Generation of cytosolic NADPH, a 
substrate for NOX1, by the pentose phosphate pathway is necessary for 
ferroptosis. These results suggest a model in which superoxide production by 
NOX1 is amplified in the cytosol by Fenton chemistry and leads to widespread 





The electron transport chain is not required for ferroptosis 
The mitochondrial electron transport chain (ETC) is a significant source of 
ROS implicated in several models of apoptotic and non-apoptotic cell death 
(Barrientos and Moraes 1999; Martinvalet, Dykxhoorn et al. 2008; Berghe, 
Vanlangenakker et al. 2010). Based on the mitochondrial localization of the 
VDAC2,3 proteins targeted by erastin, we hypothesized that the ETC was a 
source of ROS necessary for ferroptosis. Depletion of mitochondrial DNA 
(mtDNA) eliminates components of ETC complexes and decreases ETC-
dependent ROS formation (Wang, Fang et al. 2008; Weinberg, Hamanaka et al. 
2010). Cells deficient in mtDNA can therefore be used to test the involvement of 
ETC-derived ROS in cell death.  Accordingly, we examined the viability of wild-
type (rho plus, $+) and mtDNA-deficient (rho zero, $0) K-RAS mutant 143B 
osteosarcoma cells (King and Attardi 1988) in response to erastin treatment.  We 
observed a slight delay in the onset of death in $0 versus $+ cells (not shown), but 
by 24 hours both cell lines succumbed to erastin-induced ferroptotic death 
irrespective of mtDNA status (Figures 3.2A,B). Similar results were obtained 
using HT-1080 $0 cells derived in our laboratory (Figures 3.2C,D). Moreover, 
treatment of HT-1080 cells with 3-nitroproprionic acid to inhibit the activity of 
complex II, the only complex of the ETC which is not affected by mtDNA 
elimination, had no effect of ferroptosis (Figure 3.2E).  Furthermore, an arrayed 
shRNA screen targeting nuclear-DNA encoded mitochondrial proteins did not 
identify subunits of the electron transport chain as suppressors of ferroptosis 
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(S.J.D. and B.R.S., unpublished data). Together, these data suggest that 
ferroptosis does not require ETC-derived ROS. 
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Figure 3.2: Disruption of the mitochondrial ETC does not prevent 
ferroptosis.  (A,C) Erastin (10 "M)-induced ferroptosis in 143B and HT-1080 $0 
and $+ cells. (B,D) qPCR validation of the absence of mtDNA-encoded 
transcripts.  (E) Erastin (10 "M)-induced ferroptosis in HT-1080 cells is inhibited 
by the positive control DFO (100 "M) but not by the complex II inhibitor 3-
nitoproprionic acid (3-NP, 1 mM). 
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NADPH oxidase-1 is a source of ROS in ferroptosis 
Given that a functional ETC is not required for ferroptosis, we considered other 
sources of cellular ROS that could be involved in ferroptosis. The NADPH 
oxidase (NOX) proteins are dedicated to production of superoxide by using 
NADPH to reduce molecular oxygen. There are five transmembrane NOX family 
members; the classical NOX family member, NOX2, is most well-studied for its 
role in innate immunity and host defense (Segal and Jones 1978; Lambeth 
2004). Other NOX family members, including NOX1, have been implicated in 
oxidative stress in transformed cells (Irani, Xia et al. 1997; Suh, Arnold et al. 
1999; Gianni, Bohl et al. 2008). We hypothesized that an NADPH oxidase 
complex (NOX) might be a source of ROS in erastin-induced death. In support of 
this hypothesis, we identified two structurally distinct NOX inhibitors, diphenylene 
iodonium chloride (DPI) and 2-acetylphenothiazine (2-APT) that rescue BJeLR, 
Calu-1, and HT-1080 cells from ferroptosis (O'Donnell, Tew et al. 1993; Gianni, 
Taulet et al. 2010) (Figure 3.3A-C and not shown). In particular, 2-APT is a 
recently identified NOX1 inhibitor that is relatively specific for NOX1 over other 
NOX family members and flavoproteins such as xanthine oxidase (Gianni, Taulet 
et al. 2010). Rescue by 2-APT is specific to ferroptosis induced by either erastin 
or RSL3, and does not prevent death induced by several pro-apoptotic agents or 








Figure 3.3: Inhibition of NADPH oxidase prevents ferroptosis. (A,B) Co-
treatment of BJeLR and Calu-1 cells with either diphenylene iodonium chloride 
(DPI; 10 "M) or 2-acetylphenothiazine (2-APT; 1 "M in BJeLR or 10 "M in Calu-
1) and erastin (4.6 "M) for 24 hours prevents erastin-induced death. Viability was 
assessed by Trypan blue exclusion. Erastin+inhibitor values are normalized to 
inhibitor alone. (C) Light microscopy of Calu-1 cells co-treated with 4.6 "M 
erastin and 1 "M 2-APT for 24 hours. (D) 2-APT rescue is specific to ferroptosis. 
BJeLR cells were co-treated with 2-APT (1 "M) and one of the following lethal 
compounds: erastin (Era, 20 "M), RSL-3 (5.7 "M), staurosporine (STS, 1 "M), 
etoposide (Etop, 170 "M), and doxorubicin (Dxr, 18.4 "M). Viability was 
assessed by Alamar blue.  
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2-APT mediated rescue of ferroptosis suggests that the ROS in ferroptosis 
might emanate from NOX1 specifically. To test this possibility, we silenced NOX1 
and its cytosolic organizing subunit NOXO1 (Banfi, Clark et al. 2003) using short 
hairpin RNAs and found 4 non-overlapping hairpins in each case that rescued 




Figure 3.4: Short hairpin RNAs directed against NOX1 and NOXO1 prevent 
ferroptosis 
 
Figure 3.4: Short hairpin RNAs directed against NOX1 and NOXO1 prevent 
ferroptosis. Calu-1 cells infected with shRNAs targeting NADPH oxidase-1 
(NOX1) (A,B) or NOX1 organizer 1 (NOXO1) (C,D) are rescued from erastin (2.5 
"M) compared to cells infected with a control shRNA construct. Infection with 
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shRNA targeting VDAC2 is shown as a positive control. Viability assessed by 
Alamar blue and light microscopy.  Data in (A,B) is representative of 3 
independent experiments and graphed as mean +/- SD. Data in (C,D) is from one 
experiment.    
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To evaluate whether inhibition of NOX1 activity could prevent ROS in 
ferroptosis, we evaluated ROS generation using the sensitive dye 
dihydrodichlorofluorescein diacetate (H2DCF-DA). 2-APT, like DFO, prevents 
ROS accumulation following erastin treatment (Figure 3.5) Together these data 
are evidence that NOX1-dependent ROS formation is necessary for ferroptosis. 
 
Figure 3.5: NOX1 inhibition prevents ROS generation during ferroptosis 
 
Figure 3.5: NOX1 inhibition prevents ROS generation during ferroptosis. 
H2DCF-reactive ROS examined in HT-1080 cells 4 hours after drug addition, 
prior to the onset of overt death (i.e. cell size is maintained).  Upper panels 
treated with DMSO + inhibitor, lower panels treated with erastin + inhibitors, as 
indicated.  This experiment has been repeated three times with similar results.  
Representative data is shown. 
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Ferroptosis is dependent on activity of the pentose phosphate pathway 
Generation of superoxide by NOX1 requires NADPH as an electron donor. 
NADPH is produced by several reactions as part of glucose and glutamine 
metabolism in cells (Figure 3.6A), including the pentose phosphate pathway 
(PPP). Several reports suggest that in cancer cells glucose and glutamine 
metabolism is directed towards production of substrates for fatty acids and 
nucleotide synthesis rather than complete oxidation to generate the maximum 
amount of ATP via oxidative phosphorylation (Warburg 1956; DeBerardinis, 
Mancuso et al. 2007; Vander Heiden, Cantley et al. 2009). In fact, a recent report 
suggests that KRAS-transformed cells growing under normoxic conditions rely on 
NADPH-generating-pentose phosphate metabolism of glucose for fuel (Weinberg 
et al 2010).  
 We hypothesized that in addition to these functions, excess NADPH could 
increase cell susceptibility to NOX-derived superoxide. To evaluate whether 
cancer cell metabolism could affect cell sensitivity to ferroptosis, we assembled a 
panel of small molecule modulators of non-OXPHOS metabolism (Table 3.1 and 
Figure 3.6A) and tested the ability of these compounds to prevent ferroptosis in 
BJeLR and HT-1080 cells (Figure 3.6B). We focused on those modulators that 
improved cell viability by >40% in both cell lines at 10 "M erastin. Under this 
condition, the best rescue was observed using 6-aminonicotinamide, a PPP 
inhibitor, and aminooxyacetic acid, a transaminase inhibitor. 2-deoxyglucose, 
which we had previously observed to partially prevent ferroptosis (Figure 2.5F) 
also rescued at a few concentrations tested in this assay. By contrast, we 
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observed no rescue by dichloroacetate, an inhibitor of pyruvate dehydrogenase 
kinase, and little rescue by oxamic acid, an inhibitor of lactate dehydrogenase A 
(LDH-A). 3-bromopyruvic acid showed substantial toxicity on its own, both by 
alamar blue and light microscopy (Figure 3.6B and not shown). Fructose-1,6-bis-
phosphate, a glycolytic intermediate and activator of pyruvate kinase-M2 
(Christofk, Vander Heiden et al. 2008) rescued cells at 10 "M erastin in each cell 
line, although it sensitized cells to ferroptosis at lower concentrations of erastin 
(data not shown). One possibility for this sensitization could be that increased 




Figure 3.6: Metabolic modulators influence ferroptosis 
 
Figure 3.6: Metabolic modulators influence ferroptosis. (A) Schematic of 
metabolic modulators evaluated for rescue of ferroptosis. Modulators are 
highlighted in green. (B) Metabolic modulators evaluated for rescue of 
ferroptosis. Modulator concentrations that increase viability of erastin-treated (10 
"M) BJeLR or HT-1080 cells over 40% are highlighted in red; grey indicates 
concentrations of modulator that decrease alamar blue fluorescence of cells only 




Table 3.1: Metabolic modulators tested 
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Because of our interest in the NADPH oxidases as a source of ROS in 
ferroptosis we were intrigued by the effect of 6-AN on ferroptosis. In cells 6-AN is 
metabolized into 6-ANADP+, which cannot be reduced and therefore inhibits 
NADPH-producing reactions including those of the oxidative portion of the 
pentose phosphate pathway (Kohler, Barrach et al. 1970; Hothersall, Gordge et 
al. 1998). NADPH is a cofactor for many biosynthetic reactions in the cell 
including fatty acid and nucleotide biosynthesis (Berg 2002). NADPH also acts as 
an electron donor in generation of superoxide by the NADPH oxidases (NOX) 
and nitric oxide synthases (NOS) (Nordberg and Arner 2001; Lambeth 2004). We 
hypothesized that NADPH could be required for ROS generation in BJeLR cells. 
We validated the rescuing effect of 6-AN in BJeLR and Calu-1 cells by Trypan 
Blue staining and light microscopy (Figure 3.7A,B). To ensure that the rescuing 
effect by 6-AN is due to suppression of the pentose phosphate pathway, we 
evaluated whether silencing of NADPH-producing enzymes of the pentose 
phosphate pathway could also prevent erastin-induced death. We found 2/5 
shRNAs directed against glucose-6-phosphate dehydrogenase (G6PD) and 1/2 
shRNAs directed against phosphogluconate dehydrogenase (PGD) prevent 
ferroptosis in Calu-1 cells by over 70% compared to control shRNA (Figure 3.7C, 
D). These hairpins effectively deplete mRNA levels of these enzymes by 40-50% 
compared to control shRNA. Furthermore, we observed that 6-AN treatment 
suppressed erastin-induced ROS increase measured by H2DCF staining (Figure 
3.7E) and also decreased the basal level of ROS in these cells. Together these 
results suggest that NADPH-producing activity of the pentose phosphate 
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pathway sensitizes tumor cells to ferroptotic cell death and connect cancer cell 




Figure 3.7: Inhibition of pentose phosphate pathway prevents ROS 
generation and ferroptosis 
 
 
Figure 3.7: Inhibition of pentose phosphate pathway prevents ROS 
generation and ferroptosis. (A,B) 6-aminonicotinamide (6-AN, 200 "M) rescues 
BJeLR and Calu-1 cells from ferroptosis (erastin, 4.6 "M). Viability was assessed 
by Trypan blue exclusion assay (A) and light microscopy in BJeLR cells (B). Data 
is shown as mean ± SD. (C) Silencing of pentose phosphate enzymes glucose-6-
phosphate dehydrogenase (G6PD) and phosphogluconate dehydrogenase 
(PGD) by shRNA rescues Calu-1 cells from ferroptosis (erastin, 2.5 "M). (D) 
Relative mRNA levels assessed by qPCR following shRNA knockdown of G6PD 
and PGD. Labels for gene-specific hairpins shown in (C) and (D) are indicated in 
(D). Data in C and D are representative of 2 independent experiments and 
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graphed as mean ± SD. (E) H2DCF-reactive ROS examined in BJeLR cells 8.5 
hours after drug addition, prior to the onset of overt death (i.e. cell size is 
maintained).  Upper panels treated with DMSO + inhibitor, lower panels treated 
with erastin + inhibitors, as indicated.  This experiment has been repeated 2 





 Oxidative stress is associated with increased aggressiveness and 
invasiveness of tumors (Kumar, Koul et al. 2008), and there is much interest in 
harnessing increased oxidative stress in tumors as a means to selectively 
eliminate cancer cells (Trachootham, Alexandre et al. 2009). We were therefore 
motivated to identify the source of oxidative stress in ferroptosis, which appears 
to be a novel cell death pathway in cancer. Somewhat surprisingly, we found that 
ferroptosis occurs independently of the mitochondrial electron transport chain. 
Both 143B-$0 and HT-1080-$0 cells, though lower in ETC-derived-ROS 
production, are equally sensitive to erastin compared to mtDNA-intact controls. 
Various ETC inhibitors such as rotenone and antimycin, which increase 
mitochondrial superoxide, do not sensitize cells to ferroptosis (data not shown). 
These observations imply that the ETC is not a source of death-inducing ROS in 
ferroptosis. Interestingly, our results point to NOX1 as a source of death-inducing 
ROS in ferroptosis. We found that application of the NOX inhibitors DPI and 2-
APT as well as silencing of NOX1 and NOXO1 prevent ferroptosis, although the 
degree of silencing remains to be confirmed by qPCR or western blotting. The 
NOX1-specific inhibitor 2-APT prevents ROS generation following erastin 
treatment. Finally, metabolic studies revealed that inhibition of the pentose 
phosphate pathway using the small molecule 6-aminonicotinamide or silencing of 
NADPH-producing enzymes also prevent ROS generation and ferroptosis. Based 
on these results and additional data (Yagoda, von Rechenberg et al. 2007; Yang 
and Stockwell 2008) (S. Dixon and B.R.S. unpublished data), we propose a 
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possible model for our observations is as follows: (1) erastin binding to 
mitochondrial VDACs triggers a change in mitochondrial permeability that favors 
the liberation of labile iron into the cytosol, (2) this free iron interacts with NOX1-
derived ROS, resulting in the amplification of ROS production through iron-
dependent Fenton and Haber-Weiss chemistry, and (3) this ROS production 




Figure 3.8: A model of VDAC2,3-dependent ferroptosis 
 
Figure 3.8: A model of VDAC2,3-dependent ferroptosis. Initially, erastin 
interaction with VDACs triggers the release of some substance from the 
mitochondria – possibly iron or an iron-mobilizing compound – that interacts with 
NOX1-derived ROS to further enhance ROS production within the cytosol.  This 
process leads to unsustainable levels of intracellular damage, ultimately resulting 
in plasma membrane permeabilization and death. The locus of NOX1 action in 




Previous studies have implicated NADPH oxidases in cell death. These 
cell death phenotypes appear to be distinct from ferroptosis. For example, NOX-
derived ROS is implicated in pathogen killing by professional phagocytes and is 
also required for a novel form of neutrophil cell death that retains host defense 
activities termed NETosis (Brinkmann, Reichard et al. 2004; Fuchs, Abed et al. 
2007). Ferroptosis shares none of the morphologic features of NETosis, such as 
nuclear envelope vesiculation or chromatin extrusion. NOX1 has also been 
implicated in superoxide generation following TNF-treatment of mouse 
fibrosarcoma cells (Kim, Morgan et al. 2007; Berghe, Vanlangenakker et al. 
2010; Vanlangenakker, Vanden Berghe et al. 2010), suggesting possible 
similarities between TNF-induced necrosis and ferroptosis. In TNF-induced 
necrosis NOX1 is found within a signaling complex containing RIP1. TNF 
stimulation leads to superoxide production and subsequent sustained JNK 
activation, which is essential for death (Kim, Morgan et al. 2007).  However, there 
are several distinctions between this model and ferroptosis.  First, TNF-
dependent necrosis is not prevented by DFO (Berghe, Vanlangenakker et al. 
2010), a powerful suppressor of ferroptosis.  Second we find that neither the 
small molecule RIP1 inhibitor Nec-1 (Figure 2.3) nor shRNA-mediated silencing 
of RIPK1 (Figure 2.4F) attenuates ferroptosis. Third, inhibition of JNK signaling 
downstream of ROS production provides no protection from cell death in our 
system (Adam Wolpaw, B.R.S., unpublished).  Finally, the cells used in our 
studies are not sensitive to TNF-induced death (data not shown). The role of 
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NOX1 in ferroptosis therefore appears to be particular to this type of iron-
dependent, oxidative cancer cell death.  
The finding that NOX1-derived ROS are a source of death-inducing 
oxidative stress in ferroptosis may explain in part the selectivity of ferroptosis for 
cancer cells. Oncogenes, including activated RAS, promote increased NOX1-
activity, either at the transcriptional level or through effects on a NOX1 regulatory 
subunit (Irani, Xia et al. 1997; Mitsushita, Lambeth et al. 2004; Gianni, Bohl et al. 
2008). While we speculate that a transcriptional mechanism is less likely in the 
cell types used in this study (K.M.L., S.J.D., and B.R.S. unpublished data), it is 
possible that RAS-RAF-MEK-ERK signaling results in phosphorylation of NOX1 
or a NOX1 regulator. In the case of NOX2, ERK1/2 phosphorylation of the 
cytosolic p47phox  regulatory component promotes its translocation to the 
membrane and association with NOX2  prior to the respiratory burst (El-Benna, 
Dang et al. 2009). By contrast for NOX1, phosphorylation of the regulator NOXA1 
(p67phox homolog) by ERK and PKA results in negative regulation of NOX1 
activity (Kim, Diebold et al. 2007; Oh, Jung et al. 2010). However the post-
translational regulation of NOX1 is subtle, as recent evidence suggests that c-
Src-mediated phosphorylation of NOXA1 or Tks4 (Tks4, NOXA1) is important for 
NOX1-mediated ROS generation at invadopodia (Gianni, Taulet et al. 2010). 
Further studies of the role of RAS-RAF-MEK signaling on NOX1 activity in 
ferroptosis may reveal additional mechanisms governing NOX1-dependent ROS 
generation. Indeed, recent discoveries of additional NOX1 binding partners 
(Tks4/5) and localizations suggest that NOX1 regulation may be context-
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dependent. NOX isoforms have since been localized to additional subcellular 
structures including calveolae, ER, endosomes, and nuclei of multiple cell types 
(Brown, Stewart et al. 2003; Hilenski, Clempus et al. 2004; Li, Harraz et al. 2006; 
Chen, Kirber et al. 2008). In ferroptosis a particularly significant question is what 
is the relationship between NOX1 and VDAC2,3? Is it merely coincidental that 
labile iron released following erastin binding to VDACs amplifies NOX1-
generated ROS or could there be coordinate regulation or signaling between 
these proteins? A recent report has suggested the possibility that NOX1 may be 
found in the mitochondrial outer membrane (Byun, Won et al. 2008), but this 
remains to be determined in ferroptosis-senstive cells. While many questions 
regarding the mechanism of NOX1 involvement in ferroptosis remain, taken 
together our observations suggest that NOX1 activity may be an interesting 
target for future anticancer therapeutics. Coincidentally, a recent independent 
study found that in the setting of oncogenic HRAS the HDAC inhibitor FK228 
could induce NOX1 expression and ROS generation resulting in death of 
transformed cells (Choudhary, Rathore et al.).  
In studying cancer cell metabolism, we observed that NADPH-generating 
pathways were important for sensitivity to ferroptosis. In particular, the small 
molecule inhibitor of the pentose phosphate pathway, 6-AN, as well as silencing 
of the NADPH-generating PPP enzymes G6PD and PGD prevented ferroptosis. 
These results substantiate a role for NADPH in ferroptosis, and together with the 
NOX1 inhibitor studies point to a role for NADPH-dependent ROS generation in 
ferroptosis. Pentose phosphate metabolism is necessary for efficient NOX 
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activity in other physiologic settings (Gupte, Levine et al. 2006). Similarly, several 
recent reports have highlighted distinctions between glucose metabolism of 
transformed cells compared to non-transformed cells and have observed 
increased NADPH generation necessary for tumor cell proliferation 
(DeBerardinis, Mancuso et al. 2007). The role of NADPH in ferroptosis suggests 
that the metabolic reprogramming of cancer cells may be used to drive tumor cell 
death in a NOX-dependent manner. 
 
Materials and Methods 
Reagents 
Rotenone, antimycin A, CCCP, 2-deoxy-D-glucose, 3-bromopyruvic acid, 6-
aminonicotinamide, oxamic acid, aminooxyacetic acid, dichloroacetate, D-
fructose 1,6 bisphosphate, 2-acetylphenothiazine, and diphenylene iodonium 
chloride were from Sigma. Oligomycin was from Cell Signaling Technologies. 
Compounds were diluted in DMSO, ethanol or water and typically used within 
one month of preparation. 
 
Cell culture 
HT-1080, Calu-1, U2OS, and 293-T cells were obtained from American Type 
Culture Collection. HT-1080 cells were grown in DMEM High-Glucose media 
(Gibco) supplemented with 10% fetal bovine serum (FBS) and 1% non-essential 
amino acids (Gibco). Calu-1 and U2OS cells were grown in McCoy’s 5A media 
supplemented with 10% fetal bovine serum. 293-T cells were grown in DMEM 
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High-Glucose supplemented with 10% FBS. When used for transfections to 
generate virus, 293-T cells were seeded in the above media lacking antibiotics.  
293-T viral collection media contained 30% HyClone FBS. 
BJ/TERT/LT/ST/RASV12 (BJeLR) and matched controls were obtained from 
William Hahn (Harvard University). BJ series cells were grown in DMEM plus 
20% M199 and 15% heat-inactivated FBS. All medias were supplemented with 
penicillin and streptomycin (Gibco). All cell lines were grown in humidified tissue 
culture incubators (Thermo Scientific) at 37oC with 5% CO2  
 
Viability measurements 
Viability was assessed using one of two viability dyes: Alamar blue fluorescence 
or Trypan Blue dye exclusion. Alamar blue (Invitrogen) is a cell-permeant 
resazurin-based dye that is reduced by metabolically active cells to rezorufin, a 
dye with red fluorescence. Fluorescence was measured 12-16 hours after alamar 
blue addition to cells using a Victor3 platereader with excitation filter at 530 nm 
and emission filter centered on 590 nm. Trypan Blue is a vital dye that is 
excluded from live cells but permeates dead cells. Trypan Blue negative and 
positive cells were counted using an automated cell counter (ViCell, Beckman-
Coulter). In addition to the staining methods, wherever possible cell morphology 
was also assessed in 6-well culture dishes by light microscopy.  
 
Metabolic modulator screen 
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BJ/TERT/LT/ST/RASV12 and HT-1080 cells were seeded at 1000 cells/well in 
clear bottom 384-well plates (Corning) the night before the experiment. On the 
day of the experiment, the seven metabolic modulators (Table S2) were 
dissolved from fresh powder into media at the highest concentration tested. A 
five point, five-fold dilution series was generated for each modulator from the 
high concentration stock. Media was removed from the 384-well plates 
containing cells and replaced with 36 "l of the media containing a given 
concentration of modulator or normal media as a control. From a plate containing 
erastin in media at tenfold the final concentration, 4 "l was added to the assay 
plate using the Biomek. In the end, each assay plate contained cells in the 
presence of a five-point dilution series of modulator (in triplicate) tested against a 
dose-response of erastin. Plates were incubated for 24 hours at 37˚C, 5% CO2. 
10 "l of a 50% alamar blue solution were added and the plate was incubated an 
additional 12 hours. Fluorescence was read on a Victor3 plate reader.  
 
Lentiviral shRNA production 
Virus production followed the protocol of The RNAi Consortium. For production of 
virus, 293-T cells were seeded in 6-well dishes in antibiotic free media (300,000 
cells/well). Twelve hours later, cells were transfected using FuGENE with shRNA 
encoding plasmid (560 ng), viral packaging plasmid (p-Delta8.9, 500 ng), and 
viral envelope plasmid (p-VSV-G, 56 ng). After 36 hours, media was removed 
and replaced with 1.6 ml Viral Collection Media. A total of 3 collections of viral 
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supernatant in VCM per shRNA were made over 36 hours and pooled. Pooled 
supernatant was centrifuged (1,300 rpm), aliquoted, and stored at -80°C. 
 
 
Lentiviral shRNA Infection 
For lentiviral infections in 384-well format, 400 Calu-1 cells were seeded per well 
the night before the infection. On the day of the infection, media was replaced 
with 38 "l media + polybrene (8 "g/ml) and 2 "l of the viral supernatant per well. 
In a few cases where puromycin resistance was less than optimal, cells were 
infected with 6 "l viral supernatant per well (Fig 3.4) Plates were centrifuged at 
2,250 x g at 37°C for 90 minutes in a tabletop Sorvall centrifuge. Plates were 
incubated for 48 hours, then the media was replaced with media containing 2 
"g/ml puromycin and incubated for 36 hours. Media was subsequently changed 
again for 36 "l Calu-1 media + 4 "l erastin-containing media. Plates were 
incubated 24 hours. Viability was assessed using alamar blue. 
 
For lentiviral infections in 6-well format, 60,000 Calu-1 cells were seeded per well 
the night before the infection. Cells were infected in the presence of 8 "g/ml 
polybrene with 150 "l viral supernatant. In a few cases where viral titer was 
assessed to be weaker than optimal, cells were infected with 300 "l viral 
supernatant (Figure 3.4) Puromycin selection, erastin treatment were the same 
as above, but scaled for 6-well format. Where assessed, viability was assessed 




Gene expression by RT-q-PCR 
Cells from 6-well format infection were harvested following puromycin selection 
and RNA was purified using the QIAshredder and QIAgen RNAeasy extraction 
kits according to the manufacturers instructions. 2 "g total RNA per sample were 
subsequently used in a reverse transcription reaction using the TaqMan RT Kit 
priming with Random Hexamers (Applied Biosystems). Primers for q-PCR were 
designed with either Primer Express or Primer3. Quantitative PCR was 
performed on triplicate samples in 96-well format using Power SYBR Green 
Master Mix (Applied Biosystems) on an Applied Biosystems 7300 Cycler set to 
absolute quantification. The change in expression of a gene between 
experimental and control conditions was computed using the DeltaDelta Ct 
method with HPRT1 as an internal reference gene. 
  
Analysis of reactive oxygen species production 
Cells were seeded in 6-well dishes at a density of 200,000 cells/well the day 
before analysis.  On the day of analysis cells were treated with test compounds 
for the indicated times, then the media was collected in a 15 mL Falcon tube, the 
cells were washed once with PBS and harvested by trypsinization and combined 
with the previously collected supernatants.  Cell were pelleted for 3 min at 1000 
rpm, then resuspended in 500 "L of a 5 "M solution of MitoSOX (Invitrogen) in 
Hanks Balanced Salt Solution (HBSS, Gibco) and incubated in the dark for 10 
minutes in a 37oC tissue culture incubator.  In other experiments, 
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dichlorodihydrofluorescein diacetate  (H2DCFDA, 25 "M) was used instead of 
MitoSOX according to this same protocol.  Cells were then pelleted, resuspended 
in 500 "L HBSS, strained through a 40 "M cell strainer (BD Falcon) into flow 
cytometry analysis tubes and analyzed using a flow cytometer (FACSCalibur, 
Beckton Dickinson), equipped with 488-nm laser for excitation.  Data was 




 Chapter 43: Investigating the Erastin-VDAC Interaction  
 
Introduction 
 The voltage-dependent anion channel proteins (VDACs) are eukaryotic 
porins located in the mitochondrial outer membrane (Zeth and Thein 2010). 
These proteins are the major means by which ions and metabolites such as ATP, 
ADP, and NADH cross the mitochondrial outer membrane (Rostovtseva and 
Colombini 1997). The VDACs have also been implicated in cell death, ER-
mitochondria signaling, and host defense (Vander Heiden, Li et al. 2001; Rapizzi, 
Pinton et al. 2002; Cheng, Sheiko et al. 2003; Rostovtseva, Tan et al. 2005; 
Sukumaran, Fu et al. 2010). Eukaryotic cells all possess at least one isoform of 
the VDAC proteins, and mammalian cells contain three isoforms, termed VDAC1, 
VDAC2, and VDAC3 (Lemasters and Holmuhamedov 2006). VDAC1 is the most 
abundant and well-studied isoform to date. Interestingly VDAC2 and VDAC3, but 
not VDAC1, were recently identified as targets of the small molecule erastin and 
represent a novel class of proteins that are involved in cancer cell death 
(Yagoda, von Rechenberg et al. 2007).  
                                            
3Experiments reported in Figures 4.1 and 4.2 were performed in collaboration 
with Andras Bauer and are described in a manuscript that has been accepted to 
Biochemistry: Bauer AJ, Gieschler S, Lemberg KM, McDermott A, and BR 
Stockwell. “Functional model of metabolite gating by human voltage-dependent 
anion channel 2.” Dr. Tatiana Rostovtseva (NIH) kindly performed the single 
channel recordings on hVDAC2 shown in Figure 4.1C. I thank Amanda Lefkowitz 
for assistance with cloning #hVDAC2. Matthew Welsch synthesized and 
characterized many of the erastin analogs shown in Table 4.1. A detailed 
discussion of synthetic procedures will be reported by him. Several other analogs 
were previously synthesized and characterized by Dr. Inese Smukste.  
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Early biophysical studies on the VDAC proteins strongly suggested that 
they are composed of a beta barrel fold with an N-terminal alpha helix of about 
twenty amino acids (Blachly-Dyson, Peng et al. 1990; Forte, Guy et al. 1987). 
The helical portion is thought to be involved in channel gating (Song, Midson et 
al. 1998). In agreement with these studies, recent solution phase NMR and x-ray 
crystallographic studies on recombinant human VDAC1 demonstrated a 19-
stranded beta barrel fold (Hiller, Garces et al. 2008; Ujwal, Cascio et al. 2008). In 
these models the helical N-terminus extends into the pore to exit on the same 
side as the C-terminus. VDAC gating behavior has been examined using isolated 
native VDAC reconstituted into planar phospholipid membranes. At low 
membrane potential, the channel is in an “open” state and favors metabolic 
anions. Higher voltages shift the channel to a “closed” state, which shows a 
slightly increased preference for cations over metabolic anions (Rostovtseva, 
Tan et al. 2005). In addition to Donnan potentials across the mitochondrial outer 
membrane (Colombini 2004), several additional factors are likely to influence 
VDAC gating behavior in cells. These include post-translational modifications 
(such as acetylations and phosphorylations), endogenous ligands (such as 
NADH and cholesterol), and interacting proteins (such as Bcl-XL and hexokinase) 
(Zizi, Forte et al. 1994; Vander Heiden, Li et al. 2001; Olsen, Blagoev et al. 2006; 
Sukumaran, Fu et al. 2010). 
Studies have implicated VDACs in both apoptotic and necrotic cell death. 
VDACs are abundant proteins in the mitochondrial outer membrane (MOM) and 
have roles in mitochondrial membrane permeabilization, cytochrome c release, 
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and initiation of apoptotic cell death (Kroemer, Galluzzi et al. 2007; Abu-Hamad, 
Arbel et al. 2009). In vitro studies have suggested that anti-apoptotic Bcl-2 family 
members promote the open state of VDAC while pro-apoptotic factors such as t-
Bid induce closure of VDAC channels and decrease the flux across the MOM 
(Vander Heiden, Li et al. 2001; Rostovtseva, Antonsson et al. 2004; Malia and 
Wagner 2007). In agreement with these data, Cheng et al. reported that VDAC2 
complexes with Bak in cells and thereby prevents Bak homo-oligomerization from 
initiating apoptosis (Cheng, Sheiko et al. 2003). By contrast, a recent study that 
evaluated cell death in VDAC-deficient fibroblasts found no resistance to death 
triggered by calcium overload, oxidative stress, or Bax/Bid treatment. This result 
calls into question previous models of how the VDACs function in apoptotic cell 
death (Baines, Kaiser et al. 2007). VDAC has also been implicated in necrosis as 
a component of the mitochondrial permeability transition pore (PTP), which plays 
a role in necrotic death following ischemia-reperfusion injury and some bacterial 
infections (Baines, Kaiser et al. 2005; Carneiro, Travassos et al. 2009). The PTP 
increases permeability of the mitochondrial inner membrane to solutes of up to 
1.5 kDa and allows mitochondrial swelling (Crompton, Virji et al. 1998; Baines, 
Kaiser et al. 2005).  
 As a ligand for VDAC2,3, erastin is a useful probe for exploring the 
properties of VDAC2,3, which are less well-characterized than VDAC1. 
Furthermore studies on the effect of erastin on VDAC2,3 function should 
elucidate the role of these proteins in VDAC-dependent ferroptosis. Erastin-
VDAC interaction is necessary for ferroptosis as silencing expression of either 
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VDAC2 or 3 improves survival of tumor cells in the presence of erastin (Yagoda, 
von Rechenberg et al. 2007). Furthermore it was recently shown that VDAC2 and 
VDAC3 fall in regions of focal amplification in many tumors (Beroukhim, Mermel 
et al. 2010), suggesting that these gene products may be involved in 
tumorigenesis and thus desirable targets for specific anti-tumor therapies.  
To better understand the interaction of erastin with VDAC2 and VDAC3, 
and the role of the erastin-VDAC complex in ferroptosis, we investigated this 
complex from several angles. First, we established a functional assay for purified 
human VDAC2 (hVDAC2) and used this assay to examine the effect of erastin on 
wild type and mutant hVDAC2. Second, we characterized the features of erastin 
necessary for ferroptosis by screening over fifty erastin analogs. These studies 
have defined features of the erastin scaffold crucial for its function and led to 
generation of tool compounds that may be used to identify the binding site for 
erastin on VDAC2,3. Finally, these investigations of the erastin scaffold have 
allowed optimization of pharmacologic properties of erastin for therapeutic 
studies using mouse tumor xenograft models.  
 
Results 
A Functional Model of Metabolite Gating by Human VDAC2  
To gain insight into the effects of erastin on human VDAC2 (hVDAC2), we 
developed an in vitro model of hVDAC2 that permits interrogation of the 
functional properties of purified hVDAC2. This system allows us to evaluate the 
effect of erastin on hVDAC2 with greater resolution. We purified recombinant 
96 
 
His6-tagged hVDAC2 protein from inclusion bodies, followed by on-column 
refolding in the presence of detergents (Yagoda, von Rechenberg et al. 2007). 
Dr. Tatiana Rostovtseva, a collaborator at the NIH, found that when this hVDAC2 
protein was reconstituted into planar lipid membranes, it forms a single channel 
with characteristic gating behavior at high potentials, similar to what has been 
reported for native VDAC (Rostovtseva, Kazemi et al. 2006) (Figure 4.1C). Full-
length hVDAC2 was subsequently incorporated into liposomes with near 100% 
efficiency by mixing the protein with a lipid mixture of phosphatidylcholine, 
phosphatidylserine, and cholesterol in a 1:1 mass ratio (Colombini 2009) (Figure 
4.1A). The creation of liposomes was verified by CryoEM (Figure 4.1B).  
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Figure 4.1: Purification of hVDAC2  
 
Figure 4.1: Purification of hVDAC2 and incorporation into liposomes and 
planar phospholipid membranes. A) SDS-PAGE of recombinant, purified 
hVDAC2 before and after incorporation into liposomes. (L) indicates 
resuspended liposomes incorporating hVDAC2, (P) indicates purified, 
recombinant hVDAC2 after elution from column in detergent micelles (S)  
indicates supernatant above liposomal precipitate. B) hVDAC2-containing 
liposomes visualized by CryoEM. C) Current trace through a single hVDAC2 
channel reconstituted into the planar lipid membrane 
(diphytanoylphosphatidylcholine) from LDAO solution. Typical single channel 
conductance of 4.1 nS in 1M KCl at pH 7.4 and voltage gating at negative 
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potentials (> -50 mV) are observed. Applied positive and negative potentials are 
indicated. Dashed line indicates zero-current level. Current records were filtered 
by using average times of 10 ms. 
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Small molecule modulators of VDACs, such as erastin, may act by 
perturbing VDAC metabolite gating. To test this hypothesis, we developed an 
assay to monitor the passage of NADH through the hVDAC2 pore.  In cells, 
NADH serves as a key substrate and regulator of hVDAC2 (Lee, Zizi et al. 1994; 
Zizi, Forte et al. 1994). To monitor NADH trafficking through hVDAC2, we 
introduced bovine lactate dehydrogenase (LDH) into liposomes by sonication, 
and removed excess LDH from the external environment by a series of washes. 
LDH serves to oxidize NADH entering the liposome, a process that is limited by 
VDAC2 permeability and which can be easily monitored by observing the 
decrease in absorbance of NADH at 340nm. Liposomes containing hVDAC2 
were subjected to the LDH-coupled gating assays and were found to have slower 
rates of NADH oxidation than samples containing LDH alone, while empty 
liposomes and liposomes containing LDH, but no VDAC2, showed little-to-no 
NADH oxidation (Figure 4.2A). These data indicate that NADH enters the 
liposomes almost exclusively through the hVDAC2 pore.  
Erastin was previously shown to bind hVDAC2 with a Kd value of 
approximately 112 nM (Yagoda, von Rechenberg et al. 2007). We evaluated the 
effect of erastin on NADH trafficking through hVDAC2. hVDAC2-liposome 
samples were incubated with varying concentrations of erastin or an inactive 
analog, erastin A8 (see Table 4.1), prior to NADH oxidation assays. By 
comparing the rates of NADH oxidation in DMSO-treated liposomes and 
compound-treated liposomes, we determined that erastin treatment increases 
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VDAC2 permeability to NADH with an EC50=52.6 ± 28.2 nM  (Figure 4.2B). In 




Figure 4.2: Development and use of VDAC2 functional assay 
 
 
Figure 4.2: Development and use of VDAC2 functional assay. A) LDH is 
incorporated into liposomes, enabling detection of NADH gating. LDH in solution 
(red) rapidly degrades NADH, while liposomes containing hVDAC2 alone do not 
(blue).  hVDAC2 liposomes incubated with LDH but not sonicated do not show 
NADH oxidation after LDH is removed by washing (gray). hVDAC2 liposomes 
incubated with LDH and sonicated show NADH oxidation even after excess LDH 
removal by washing, indicating LDH incorporation (orange). Empty liposomes 
sonicated with LDH show very little NADH oxidation (purple) indicating that 
VDAC2 is responsible for NADH gating in hVDAC2 liposomes. B) Relative NADH 
oxidation rates in wild-type VDAC2-containing liposomes, normalized to oxidation 
rates observed with DMSO treatment. C) Relative NADH oxidation rates in N-
terminal-truncated VDAC2-containing liposomes, normalized to oxidation rates 




We then investigated the possible involvement of the N-terminal loop in 
VDAC2 gating and erastin binding by expressing a truncated version of hVDAC2 
lacking the first 20 amino acids ($hVDAC2). N-terminal truncations of VDACs 
have previously been described to be functional in lipid-bilayer gating 
experiments but show altered voltage-dependence and decreased initiation of 
cell death (Rostovtseva, Kazemi et al. 2006; Abu-Hamad, Arbel et al. 2009). 
LDH-coupled gating assays with $hVDAC2 liposomes exhibited 30% lower 
permeation rates than observed for the wild-type hVDAC2 (data not shown). 
Erastin displayed no effect on NADH permeability in $hVDAC2 liposomes at sub-
micromolar concentrations, suggesting involvement of the N-terminal region in 
mediating erastin’s effect on metabolite gating (Figure 4.2C). At the highest 
concentration tested, 10 "M, a strong positive effect was observed on NADH 
permeability (Figure 4.2C). Consistent with these data is the observation that N-
terminal mutants of Neurospora crassa VDAC have an increased preference for 
the cation-selective “closed” state (Popp, Court et al. 1996). The N-terminal 
deletion of $hVDAC2 may similarly shift the channel into the closed state and 
cause a decreased basal rate of NADH permeation through the channel, thus 
amplifying an effect of the highest concentration of erastin in our analysis. 
Whatever the mechanism, the high concentration of erastin makes it less 
relevant to erastin’s activity in cells. 
In conclusion, we have created an in vitro functional system for monitoring 
metabolite gating of hVDAC proteins. This system was also compatible with solid 
state NMR studies on hVDAC2 performed by Dr. Simone Gieschler in the 
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McDermott lab, which confirmed that hVDAC2 was in a beta-barrel-like 
confirmation that is altered slightly upon erastin binding. Future studies using this 
system will enable high-resolution structural characterization of hVDAC2 and 
hVDAC2-erastin complexes. Using this system, we determined that high 
nanomolar concentrations of erastin affect metabolite gating of hVDAC2. 
However, an N-terminal truncation mutant of VDAC2 is resistant to this effect of 
erastin over the same range of concentrations. These studies should aid in 
understanding VDAC2 gating mechanisms and in developing novel anti-tumor 
agents. 
 
Optimization of the Erastin Scaffold 
 As a second approach to characterize the erastin-VDAC interaction we 
investigated the in-cell activity of over fifty erastin analogs to define regions of the 
erastin scaffold required for ferroptosis. These studies also provided information 
about where erastin may be modified to generate affinity-labeling probes for 
future erastin-VDAC2 binding site studies. Both chemical and photoaffinity 
labeling analogs of small molecules have been useful in previous studies to 
define interacting target proteins and binding sites on established targets (Karlin 
and Winnik 1968; Chen, Heim et al. 2003; Kinoshita, Cano-Delgado et al. 2005; 
Cohen, Hadjivassiliou et al. 2007). An additional goal of this work was to optimize 
an erastin-based compound to study ferroptosis in mouse tumor models. For this 
purpose, we wanted to improve both erastin’s potency and its pharmacokinetic 
properties. Unfortunately the parental erastin is not very soluble in aqueous 
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solvents (calculated logS = -7.3), and preliminary pharmacokinetic studies 
suggested that erastin might be metabolized into inactive derivatives, such as a 
des-ethyl compound (IS-240H; Table 4.1). Improving both compound solubility 
and metabolic stability will likely improve the outcome of animal studies. 
 To date, over 65 erastin analogs have been synthesized and tested in a 
RAS-selective lethal assay. This assay compares the dose-response curves of 
erastin (or an analog) in four engineered fibroblast cell lines of increasing 
tumorigenicity (Hahn, Counter et al. 1999; Yang and Stockwell 2008). The 
parental erastin typically has an EC50 of approximately 1.5-2 "M in two HRASV12 
transformed cell lines but an EC50 well over 10 "M in isogenic immortalized, non-
transformed fibroblasts (BJeH cells). This translates to a selectivity of 
approximately eight-fold for BJeLR cells over BJeH cells (Dolma, Lessnick et al. 
2003). 
Table 4.1 lists approximately 90% of the erastin analogs tested along with 
their EC50 values in BJeLR cells. We have also defined a parameter known as 
the selectivity score which is a ratio of the EC50 value in non-transformed cells 
(BJeH) compared to in oncogenic RAS expressing cells (BJeLR) (Dolma, 
Lessnick et al. 2003). One significant finding from these studies was identification 
of the compound known as DIerastin (3MEW28), which eliminates the chiral 
center but retains activity. Erastin was previously used as a mixture of 
atropisomers (stereoisomers with hindered rotation of the aniline ring). This 
modification is a significant improvement as new analogs based on the DIerastin 
scaffold are present as pure compounds. Furthermore DIerastin contains on o-
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isopropoxy group on the aniline ring, rather than an o-ethoxy group. We 
speculate that this branched modification may be less susceptible to O-
dealkylation to inactive metabolites. An additional increase in potency and 
selectivity was gained by modification of the 6-position on the quinazolinone to 
an aniline (6MEW160), which has over 20-fold selectivity for BJeLR cells 
compared to BJeH cells. Other modifications eliminate erastin’s RAS-selective 
lethal activity. For example, altering the either the piperazine group (4MEW70, 
4MEW113, 5MEW68) or the linker between the piperazine and the p-
chlorophenolic group eliminated activity (3MEW89, 5MEW7, 5MEW22). 
Modifications to the quinazolinone core structure tended to reduce potency in 
BJeLR cells but retain some selectivity (6MEW78, 9MEW12). Based on these 
studies, an activity map for erastin has been generated (Figure 4.5). This 
information should help guide future analog synthesis.  
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Figure 4.3: A molecular activity map for erastin 
 




Identification of POX-Tfd-erastin A2—A Potential Photoaffinity Labeling 
Erastin 
 An additional goal of the erastin analog studies is to identify regions of the 
molecule that may be modified to generate improved affinity label compounds for 
future erastin-VDAC binding site studies. We identified an active, selective 
analog (erastin A2) containing a primary amine which we hypothesized would be 
a good site for modification of the scaffold. As the propargoxy modification of 
erastin also retains activity, we had the propargoxy derivative of erastin A2 
commercially synthesized (POX-erastin A2; Table 4.1). POX-erastin A2 was also 
active and selective in our Ras-selective lethal assay. We subsequently used 
POX-Era-A2 to prepare two potential ligands for erastin binding site discovery. 
The first of these was a chloroacetamide analog of POX-Era-A2 (CAM-POX-
erastin A2 or KML-6A). This compound should act as a chemical affinity label for 
purified VDAC2. Matthew Welsch also prepared a photoaffinity labeling derivative 
using a 3-trifluoromethyl-3-phenyldiazirine (Brunner, Senn et al. 1980). The acid 
version of this compound (4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoic acid) 
was coupled to the amine of POX-Era-A2 to yield POX-Tfd erastin A2 (Table 
4.1). 
 These two analogs have subsequently been tested in the Ras-selective 
lethal assay to determine whether they exhibit similar potency and selectivity to 
erastin. Both analogs are lethal to cells expressing oncogenic RAS, but CAM-
POX-erastin A2 is not selective for cells expressing oncogenic Ras and is lethal 
to all four BJ cell lines with an EC50 of approximately 5 "M (Table 4.1). Tfd-POX-
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erastin A2 has an EC50 of 3.7 "M and over 25-fold selectivity for cells expressing 
oncogenic RAS (Fig. 4.6A). BJeLR cells were rescued from POX-Tfd-erastin A2 
by co-treatment with DFO, U0126, and butylated hydroxyanisole, an antioxidant 
(Figure 4.6B), consistent with induction of ferroptosis by this analog. While the 
VDAC2-dependence of Tfd-POX-erastin A2 remains to be evaluated, this analog 
appears to be a very promising candidate to pursue future binding site studies 
with purified VDAC2.  
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Figure 4.4: POX-Tfd-erastin A2 is a potential photoaffinity labeling erastin 
 
Figure 4.4: POX-Tfd-erastin A2 is a candidate for future VDAC-binding site 
studies. A) Dose response curves of four BJ cell lines in response to 
photoaffinity-labeling erastin analog. Analog structure of POX-Tfd-erastin A2 is 
depicted in Table 4.1. Cell line abbreviations are as follows: BJ/TERT (BJeH), 
BJ/TERT/LT/ST (BJeHLT), BJ/TERT/p53DD/CDK4R24C/cyclinD1/ST/RASV12 
(BJ(DRD)), BJ/TERT/LT/ST/RASV12 (BJeLR). B) Response of BJeLR cells to 
cotreatment with small molecules that rescue ferroptosis: deferoxamine (DFOM), 
U0126 (MEK inhibitor), butylated-hydroxyanisole (BHA). 
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Improving erastin’s solubility 
Our analysis of the erastin scaffold also yielded analogs with improved 
solubility. The p-chlorophenoxy group, while required for activity, greatly hinders 
aqueous solubility of erastin both by calculation of logS and experimental 
determination of solubility. To improve solubility for in vivo studies, erastin 
analogs with addition of hydrophilic moieties were synthesized and tested (Table 
4.1). The primary amine on erastin A2 was modified with several hydrophilic 
groups such as tertiary amines and imidazoles (5MEW70, 71, 94, 6MEW19). Of 
these analogs, 6MEW19 retained activity and 8-fold selectivity for BJeLR cells. At 
the 6-quinazolinone position, addition of a methylene morpholine (9MEW96) also 
retained activity and selectivity, although the potency in BJeLR cells was reduced 
somewhat compared to erastin. When solubility was measured, 9MEW96 has 






Ferroptosis is a novel VDAC2,3-dependent death induced by erastin. 
Since erastin is a selective modulator of VDAC2 and VDAC3, we were motivated 
to use erastin to probe VDAC2,3 function. We initially chose to study the erastin-
VDAC2 interaction because VDAC2 is more amenable to recombinant 
expression and purification. In the NADH-coupled gating assay we observed that 
erastin increases the rate of NADH trafficking through hVDAC2 into liposomes 
containing bovine LDH. This effect of erastin was specific, as the inactive erastin 
A8 did not augment the rate of NADH oxidation. This assay for hVDAC2 function 
is also particularly significant in that it takes place in a context that permits side-
by-side structural studies of hVDAC2 by solid-state NMR. An advantage to our 
system is that functional and structural data are obtained within the same lipid 
environment. Previous studies of VDAC structure have been performed using 
detergent micelles (Hiller, Garces et al. 2008), which is quite a different 
environment for the protein than the planar phospholipid bilayer in which 
functional studies are usually performed. Whether erastin in living cells also 
increases the rate of NADH trafficking through VDAC2 into the mitochondria is an 
open question. In eukaryotic mitochondria VDAC2 may have post-translational 
modifications or other binding partners that also affect its function. It is possible 
that erastin affects trafficking of other metabolites through VDAC2 as well. 
Interestingly however we observed that the N-terminal truncation, #hVDAC2, was 
insensitive to the effects of erastin in the same range as the full-length protein. 
This suggests that the N-terminal helical region is necessary for erastin’s 
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modulation of VDAC2 function. It will be interesting to further evaluate whether 
this region is directly involved in erastin-VDAC2 binding. We also were interested 
in evaluating VDAC mutants for whether they remain competent to bind erastin in 
cells and induce ferroptosis. Because of the redundancy of VDAC2 and VDAC3 
in ferroptosis, designing these experiments is somewhat challenging. One 
strategy we considered was to express VDAC2 mutants such as #hVDAC2 in an 
environment devoid of endogenous VDAC2 and VDAC3 expression. We 
attempted to initiate studies using VDAC-knockout MEFs for this purpose, but in 
characterizing these MEFs we found that this cell type would not be suitable for 
these experiments (Appendix A).  
The synthesis and testing of many erastin analogs has allowed us to 
define the regions of erastin’s scaffold that are essential for induction of 
ferroptosis. While several regions of the parental compound were identified that 
tolerate modification, we found more rigid requirements for structural integrity of 
the piperazine ring and the p-chlorophenoxy group. These result suggest that 
these regions mediate critical and specific contacts with receptors involved in the 
cell death phenotype. Erastin A8, which differs from erastin in the presence of the 
p-chlorophenoxy group neither induces ferroptosis nor modulates hVDAC2 
gating in the functional assay. This result suggests that this region of the 
compound is important for affecting VDAC2 function. 
To better understand how erastin binding to VDAC2,3 affects channel 
structure and function, it would be very useful to identify the binding site for 
erastin on these proteins. An initial attempt that was made to locate the erastin 
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binding site on VDAC2 using a chemical affinity labeling strategy was 
unfortunately not successful (Appendix B). Our explorations of the erastin 
scaffold revealed additional regions available for modification with photoaffinity 
labels. Photoaffinity labels, such as diazirines and benzophenones, have the 
capacity to label proteins both at side chain and backbone carbons when 
activated by UV light (Vodovozova 2007). The newly-synthesized compound 
POX-Tfd erastin A2, with its similar potency and superior selectivity compared to 
parental erastin appears to be a strong candidate for future binding site studies. 
To facilitate use of this photoaffinity labeling compound, we have set up a 
collaboration with the Turro group in the Department of Chemistry. They will 
assist us in characterizing the photoactivity of the diazirine alone and once it is 
coupled to the erastin scaffold. These studies should permit us to establish 
reactivity of the carbene generated on photolysis and determine the conditions to 
use to label purified VDAC2. Ideally it would be useful to determine the VDAC2,3 
dependence of Tfd-POX-erastin A2 activity in cells before beginning these 
studies. This may be done in cells by silencing VDAC2 or 3 expression. 
Furthermore Tfd-POX-erastin A2 may be tested in the newly described NADH-
coupled gating assay to ensure it has similar activity to erastin. 
Several regions that show structural flexibility have been modified to 
improve erastin’s potency in BJeLR cells, degree of selectivity, and solubility. A 
notable improvement in solubility was made upon addition of a morpholine group 
to the 6-position on the quinazolinone. Although this has not yet clearly translated 
into activity in a mouse tumor xenograft model, it represents a significant step 
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forward in that the compound could be dosed in aqueous solvent. With further 
simultaneous improvements in compound potency in RAS-activated tumor cells 
and solubility we are optimistic that erastin analogs with more drug-like properties 
will be successful in therapeutic animal studies. 
 
Materials and Methods 
Cloning of hVDAC2 and #hVDAC2 
Full-length hVDAC2 was cloned into, and expressed from, pDEST-17 
(Invitrogen) as previously described (Yagoda, von Rechenberg et al. 2007). To 
delete the twenty N-terminal amino acids of hVDAC2, the following primers were 
used:  
Forward primer:  5’-G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC CTT GGC AAA 
GCT GCC AGA GAT-3’ 
Reverse primer:  5’ – GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC CTA AGC CTC 
CAA CTC CAG GGC – 3’ 
 
The forward PCR primer was designed to anneal to the VDAC2 cDNA 
template beginning 60 base pairs in from the start codon. Both primers also 
contained attB recombination sites in the flanking DNA. PCR was performed 
using pENTR-VDAC2 as the template. The PCR product was purified and 
recombined into pDONR-221 (Invitrogen) according to the manufacturers 
instructions. The template for #hVDAC2 was subsequently recombined into 
pDEST-17 (Invitrogen) for expression and purification. Conditions for expression 





Bacterial cultures (BL21(DE3) E. coli transformed with either pDEST17-
hVDAC2 or pDEST17-#hVDAC2 vector) were grown in 4 x 1 liters LB broth 
containing 50 mg/L ampicillin to an absorbance of 0.6 (!=600 nm). Protein 
expression was induced by 0.4 mM IPTG and 0.2% w/v L-Arabinose overnight. 
Cultures were harvested by centrifugation at 6,000 x g for 10 min. The pellet was 
washed with distilled H2O and resuspended in lysis buffer (50 mM Tris-HCl pH 
7.5, 100 mM NaCl, 20% sucrose, 0.6% Triton-X 100, 5 µg/ml lysozyme) and 
incubated at 25° C for 10 min. The lysate was then sonicated 2 x 30 s in a 
Branson sonicator and centrifuged at 15,000 x g for 20 min. The pellet was 
resuspended in resuspension buffer (6 M guanidine-HCl, 100 mM NaCl, 50 mM 
Tris-HCl pH 8.0) and incubated for 1 h at 25° C with rotation. The suspension 
was then centrifuged (20 min, 15,000g), and the supernatant diluted with 100 mM 
NaCl, 50 mM Tris-HCl pH 8.0 to reach a guanidine-HCl concentration of 4.5 M. 
The solution was loaded at 4˚C on a Ni-NTA Superflow column (Qiagen) pre-
equilibrated with five volumes of resuspension buffer. The column was washed 
with five column volumes of wash buffer (100 mM NaCl, 50 mM Tris buffer (pH 
8.0), 4.5 M guanidine- HCl), followed by one column volume of a low imidazole 
wash (wash buffer containing 25mM imidazole).  
For elution in detergent micelles: The protein was refolded on the 
column after the low-imidazole wash in a buffer containing 0.4% LDAO (N,N-
Dimethyldodecylamine N-oxide), 0.1M NaCl and 50mM Tris-HCl pH 8.0. The 
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column was washed in three column volumes of the refolding buffer and eluted 
with 50 mL refolding buffer containing 250 mM imidazole.  
For elution in detergent micelles, followed by flash refolding into 
liposomes (used in labeling of purified VDAC2 with probe and NADH-coupled 
gating assay): The protein was refolded on the column after the low-imidazole 
wash in a buffer containing 0.4% LDAO (N,N-Dimethyldodecylamine N-oxide), 
0.1M NaCl and 50mM Tris-HCl pH 8.0. The column was washed in three column 
volumes of the refolding buffer and eluted with 50 mL refolding buffer containing 
250 mM imidazole. Purified, refolded hVDAC2 or $hVDAC2 protein was diluted 
in a 1:1 mass ratio with 50 mM Tris buffer (pH 7.5), 100 mM NaCl, 1 mM DTT, 2 
mg/ml phosphatidylcholine, 0.5 mg/ml phosphatidylserine, 0.25 mg/ml 
cholesterol, and 1% LDAO to a total volume of 1 mL per dialysis chamber. The 
sample was dialyzed into 2 L of dialysis buffer (50 mM Tris-HCl pH 7.5, 100 mM 
NaCl, 1 mM DTT) for 12 hours, after which the dialysis buffer was changed. We 
continued dialyzing for 2 days, changing dialysis buffer every 12 h. Precipitate 
would appear typically after 36 hours, usually containing %95% of the protein. 
The precipitate was subsequently analyzed by SDS-PAGE to monitor 
incorporation of the protein (Figure 4.3A). 
Imaging of Liposomes in Precipitate: To determine the presence of 
liposomes in the precipitate, samples of precipitated hVDAC2 and precipitated, 
sonicated $hVDAC2 in ddH2O were subjected to Cryo-EM imaging at the 
NYSBC. The analysis revealed the presence of mainly unilamellar liposome 
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vesicles with diameters between 50-300 nm. The fraction of multilamellar 
liposomes and average diameter increased following sonication (not shown.) 
 
NADH gating assay 
 The assay makes use of the reaction catalyzed by lactate dehydrogenase 
(LDH), an enzyme that converts pyruvate and NADH to lactate and NAD+.  We 
introduced bovine heart LDH (Sigma) into VDAC-containing liposomes by 
sonication. Precipitated liposomes containing ~1mg of VDAC2 were pelleted by 
centrifugation in a 4°C tabletop centrifuge at 10,000 rpm for 10 min.  The pellet 
was resuspended in 500 µL PBS, then mixed with 20 units LDH. The sample was 
sonicated for 12 sec on a low power setting (36-40 J of energy output) using a 
Branson Sonifier, after which the liposomes were spun down as before, washed 
three times in 500 µL of cold PBS, and resuspended in 250 µL PBS per mg of 
protein.   
 Each assay sample measured contained 10-15 "l precipitate in 500 "l 
PBS buffer supplemented with 30 "l of 100 mM sodium pyruvate. Samples were 
pretreated with erastin, erastin A8, or DMSO (0.5 "l) for at least 5 minutes prior 
to obtaining spectra. The solution was transferred in to a quartz cuvette and 
placed in a spectrophotometer (Beckman-Coulter, System Gold 168). After 
monitoring the baseline for 30 seconds, NADH was added to a final 





BJ/TERT/LT/ST/RASV12 (BJeLR) and matched controls were obtained from 
William Hahn (Harvard University). BJeLR cells were grown in DMEM High-
Glucose media (Gibco) plus 20% M199 (Sigma) and 15% heat-inactivated fetal 
bovine serum (FBS). All cell lines were grown in humidified tissue culture 
incubators (Thermo Scientific) at 37oC with 5% CO2.  All medias were 
supplemented with penicillin and streptomycin (Gibco). 
 
Screening compounds in 4 BJ cell lines 
Cells from four BJ cell lines were seeded the night before the experiment in 384-
well format at 1000 cells/well in 40 "l volume. Compounds were dissolved in 
anhydrous DMSO to a stock concentration of 100 mM. Stocks were diluted into 
media to a concentration of 200 "M. A 384-well daughter plate was filled with 
media (30 "l/well) in all wells except columns 3 and 13. Wells 3 and 13 were 
filled with compound stocks in media and diluted manually across the plate using 
a multichannel pipette. The media above the cells was replaced with 32 "l of 
fresh media. 8 "l per well from the compound daughter plate were diluted into the 
assay plate using either the Biomek or a multichannel pipet. Assay plates were 
incubated for 24 hours and viability was assessed using alamar blue.  
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Table 4.14: Erastin Analogs Evaluated for Activity in BJ Cell Lines 
 
                                            

































Chapter 5: Perspectives and Future Directions 
 
Summary 
 This thesis defines ferroptosis as a novel, oxidative cancer cell death 
phenotype induced by the small molecule erastin. Ferroptosis is distinct from 
previously studied forms of cell death including apoptosis, classical and 
programmed necrosis, and autophagic cell death. Significant features of 
ferroptosis include aberrant mitochondrial morphology and an increase in cellular 
ATP levels. Ferroptosis does not require a functional electron transport chain. 
Death-inducing ROS are produced in a NOX1-dependent manner, and non-
oxidative glucose metabolism via the pentose phosphate pathway sensitizes 
cells to ferroptosis. Ferroptosis also depends on the interaction of erastin with the 
VDAC2,3 proteins (Yagoda, von Rechenberg et al. 2007). In the presence of 
erastin, but not an inactive erastin analog, the rate of anionic metabolite 
trafficking through purified hVDAC2 increases. The erastin scaffold was explored 
for cell-based activity using many erastin analogs and has resulted in mapping 
erastin’s activity to particular regions of the scaffold. These studies have led to 
generation of tool compounds for future in vitro and in vivo studies on ferroptosis. 
The name ferroptosis was given to erastin (as well as RSL3 and RSL5)-
induced cell death because a defining feature of the cell death is a reliance on 
labile iron (Yagoda, von Rechenberg et al. 2007; Yang and Stockwell 2008). Iron 
chelators and genetic manipulation of cellular iron homeostasis affect the 
outcome of erastin treatment. While the work presented here does not directly 
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address the role of iron in ferroptosis, Dr. Scott Dixon and others in the lab are 
currently investigating alterations in iron homeostasis that occur during 
ferroptosis. These studies include work to understand the overall levels, 
localization, and oxidation state of labile iron in ferroptosis-sensitive cells as well 
as cellular mechanisms for regulating iron homeostasis.  
 
Ferroptosis is a Novel Cell Death 
To determine whether erastin induces a previously-identified mode of cell 
death or represents a newly-characterized cell death phenotype, we evaluated 
ferroptosis in relation to three major modes of cell death (apoptosis, autophagy, 
and necrosis) as well as several alternative modes of programmed necrosis 
(Galluzzi, Aaronson et al. 2009; Kroemer, Galluzzi et al. 2009). We employed 
multiple methodologically unrelated procedures to characterize ferroptosis, 
including studies of cell morphology, chemical and genetic suppression, 
functional events, and bioenergetics. Prior to this work it had been shown that 
erastin treatment causes cell death with loss of plasma membrane integrity within 
8-12 hours (depending on cell type), and cells do not recover from this process 
upon removal of erastin (Dolma, Lessnick et al. 2003; Yagoda, von Rechenberg 
et al. 2007). Ferroptosis bears no resemblance to apoptosis either by the 
traditional morphologic definition or by biochemical analyses (Yagoda, von 
Rechenberg et al. 2007). Unlike staurosporine- or camptothecin-treated (e.g. 
apoptotic) cells, erastin-treated cells do not undergo early cell shrinkage, 
increased cytoplasmic density, chromatin margination, nuclear fragmentation, or 
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membrane blebbing (Dolma, Lessnick et al. 2003). Effector caspases are not 
cleaved and activated upon erastin treatment. Classical caspase substrates such 
as PARP1 are not hydrolyzed during ferroptosis. Ferroptosis is independent of 
pro-apoptotic Bcl-2 family members BAX and BAK. The mitochondria in 
ferroptosis do not undergo MOMP to release pro-apoptotic factors such as 
cytochrome c (Yagoda, von Rechenberg et al. 2007). Together these studies 
distinguish ferroptosis from apoptosis and motivate investigation of ferroptosis in 
anti-tumor studies, as tumor cells frequently lose the ability to carry out apoptosis 
(Fisher 1994; Hanahan and Weinberg 2000).  
Ferroptosis lacks hallmarks of autophagic cell death, including formation 
of double-membrane enclosed autophagosomes and massive cytoplasmic 
vacuolization. Pharmacologic suppressors of distinct points in autophagosome 
formation do not prevent ferroptosis. By morphology, functional assays, and 
bioenergetics ferroptosis is also distinct from classical necrosis. Cellular and 
organelle swelling are absent during ferroptosis, and the plasma membrane is 
disrupted only many hours after erastin treatment. Cellular ATP levels actually 
increase, rather than decline, during cell death. Furthermore ferroptosis is 
suppressed by a unique set of small molecule and genetic modulators (S. Dixon 
and B.R.S. unpublished), showing that the cell death does not result from 
widespread, non-specific toxicity of a lethal stimulus.  
In recent years a number of alternative death phenotypes have been 
described in mammalian cells, some in vivo but others only in vitro. These 
phenotypes include necroptosis, entosis, NETosis, granzyme A-mediated cell 
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death, TNF-alpha induced necrosis, and PARP-dependent necrosis (Brinkmann, 
Reichard et al. 2004; Zong, Ditsworth et al. 2004; Degterev, Huang et al. 2005; 
Martinvalet, Zhu et al. 2005; Kim, Morgan et al. 2007; Overholtzer, Mailleux et al. 
2007). Some of these phenotypes, such as entosis and NETosis, have been 
primarily observed in specific tissues and cell types and have very different 
morphologies from ferroptosis. Many of these alternative phenotypes, including 
granzyme-A mediated cell death, TNF-induced necrosis, and necroptosis in 
some cell types also involve production of ROS, but differ from ferroptosis in 
other significant ways. In the case of granzyme-A toxicity, ROS are produced 
from the ETC, whereas ferroptosis does not require a functional ETC to induce 
oxidative stress (Martinvalet, Dykxhoorn et al. 2008). Ferroptosis is distinct from 
TNF induced necrosis and necroptosis in that it does not require the activity of 
the kinase RIP1 (Vercammen, Beyaert et al. 1998; Kim, Morgan et al. 2007; 
Degterev, Hitomi et al. 2008). In summary we find that ferroptosis is distinct from 
apoptosis, autophagy, necrosis, and many alternative cell death mechanisms. 
Ferroptosis is defined by alterations in mitochondrial morphology and increased 
ATP levels upon cell death. Erastin-induced ferroptosis is further unique in that 
erastin targets the VDAC2,3 proteins, and erastin-induced ferroptosis, but not 
other forms of cell death, is suppressed by silencing of VDAC2 or VDAC3.  
These VDAC isoforms have not been previously implicated in non-apoptotic cell 
death. 
Many of our studies use cell viability (by dye-based or other) techniques to 
measure ferroptosis in conjunction with chemical suppression by iron chelators, 
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antioxidants, and MEK inhibitors. In the future it would be extremely desirable to 
define a specific biochemical marker of ferroptosis that could be used in 
conjunction with other studies to identify ferroptosis, either in cell culture or in 
vivo studies. Investigations of several other forms of cell death have been greatly 
facilitated by such a marker, such as cleaved caspase-3 (apoptosis), LC3-II 
(autophagy), and phosphorylation of RIP1 (programmed necrosis) (Srinivasan, 
Roth et al. 1998; Kabeya, Mizushima et al. 2000; Degterev, Hitomi et al. 2008; 
Cho, Challa et al. 2009). From our characterization of ferroptotic cell death, the 
primary distinguishing features of ferroptosis are smaller, condensed 
mitochondria visualized by TEM and increased ATP levels. The methods used to 
detect these changes are either quite low-throughput or not amenable to looking 
at large populations of different cell types in tissue sections/animal models and 
would need to be optimized for further studies. Another option as a marker of 
ferroptosis might be particular forms of oxidative damage such as lipid 
peroxidation products. Lipid peroxidation and formation of reactive aldehydes 
occur during ferroptosis (K.M.L., W. Yang and B.R.S., unpublished). Dr. Wan 
Seok Yang is continuing to pursue the role of lipid peroxidation in ferroptosis, 
although it is not yet clear how specific lipid peroxidation products are for 
ferroptosis over other oxidative death processes. Finally, microarray studies and 
follow up led to identification of genes that are upregulated during ferroptosis. 
One candidate gene is CHAC1, which encodes a pro-death gene downstream of 
the unfolded protein response (Mungrue, Pagnon et al. 2009). Scott Dixon, 
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Caroline Gleason, and Egbe Ode are pursuing this candidate as a marker of 
ferroptosis.  
  
NOX1 is a Source of Death-Inducing ROS in Ferroptosis 
 We found that generation of ROS during ferroptosis depends on activity of 
NADPH oxidases, specifically NOX1. Ferroptosis is prevented by two different 
inhibitors of NOX activity, including 2-APT, a NOX1-specific inhibitor (Gianni, 
Taulet et al. 2010). Inhibition of NOX1 by 2-APT specifically rescues cells from 
ferroptosis, but not from several pro-apoptotic agents. Furthermore silencing of 
the catalytic NOX1 gene or NOXO1, a cytoplasmic subunit necessary for NOX1 
activity, prevents ferroptosis (Banfi, Clark et al. 2003). Based on these results, 
we currently favor a model for ferroptosis in which erastin binding to 
mitochondrial VDACs induces relocalization of a pool of labile iron into the 
cytosol. This iron interacts with basal ROS produced by NOX1 and oxidative 
stress is amplified by iron-dependent Fenton chemistry (see Chapter 3, Figure 
3.7). Increased oxidative stress subsequently overwhelms cellular antioxidant 
defenses and damages macromolecules, such as lipids and DNA, leading to cell 
death.  
 To test the validity of this model, we have identified several directions for 
future experiments. First, it will be important to confirm the role of NOX1 in basal 
ROS generation in erastin-senstive cells. We are working to confirm the degree 
of knockdown by qPCR or western blotting. This confirmation step has been 
partially hindered by a lack of good NOX1-specific antibodies. NOX1 or p47phox-
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null MEFs may also be useful in establishing a role for NOX1 in ferroptosis. It has 
been shown experimentally that p47phox may substitute for NOXO1 and 
hypothesized that this may be a relevant NOX1 organizer in certain cell types 
(Bedard and Krause 2007). Additionally we would like to evaluate whether any 
other NOX isoforms provide a source of ROS in ferroptosis and as an initial step 
we have obtained shRNA-constructs against NOX2 to test whether silencing this 
isoform also prevents ferroptosis. Second, we would like to better understand the 
biology of NOX1 in ferroptosis-sensitive cells. While NOX1 activity appears to be 
necessary for ferroptosis, our model suggests that it is not sufficient. This aspect 
of the model could be evaluated first by examining whether NOX1 complex 
expression sensitizes ferroptosis-resistant cells to erastin. We have obtained a 
set of NOX1 complex expression plasmids that could be used for this purpose 
(Gianni, Bohl et al. 2008). Additionally endogenous NOX1 activity may be 
increased by overexpression of constitutively active RAC1 (RAC1Q61L); it would 
be informative to know whether increasing basal NOX1 activity further sensitizes 
to ferroptosis. Furthermore, it would be useful to learn why NOX1 activity 
provides a source of ROS in ferroptosis-sensitive cells. Several reports suggest 
that oncogenic RAS transcriptionally upregulates NOX1 (Mitsushita, Lambeth et 
al. 2004; Adachi, Shibai et al. 2008). Preliminary data suggests that this does not 
account for enhanced NOX1-derived ROS in ferroptosis-sensitive cells. Another 
possibility is that RASV12 drives NOX1 activity by activating RAC1 in these cells 
(Irani, Xia et al. 1997). Preliminary results suggest that silencing of RAC1 may 
partially prevent ferroptosis. Alternatively, activated RAS-RAF-MEK-ERK 
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signaling may increase the activity of NOX1 or an undefined NOX1 regulator in a 
transcription-independent manner. Previous reports showed that phosphorylation 
of the regulator NOXA1 (p67phox homolog) by ERK and PKA results in negative 
regulation of NOX1 activity (Kim, Diebold et al. 2007; Oh, Jung et al. 2010). 
However, a recently-identified NOX1 regulator (Tks4) appears to be activated by 
phosphorylation downstream of the tyrosine kinase c-Src (Gianni, Taulet et al. 
2010). This suggests that regulation of NOX1 activity may be subtle and context-
dependent. Perhaps in ferroptosis-sensitive cells NOX1 regulation and/or 
localization differs from other cell types in which NOX1 has typically been studied 
(Suh, Arnold et al. 1999).  
Tumor cells frequently have increased levels of endogenous ROS 
compared to healthy counterparts, suggesting that oxidative stress is important in 
development and progression of cancer (Toyokuni, Okamoto et al. 1995; Petros, 
Baumann et al. 2005; Trachootham, Zhou et al. 2006). Given this difference 
between cancer cells and healthy cells, there is interest in using tumor-derived 
ROS to induce cancer cell-selective toxicity (Trachootham, Alexandre et al. 
2009). In this light there is the potential that our studies on the biology of NOX1-
derived ROS in ferroptosis could reveal interesting avenues for future anti-tumor 
research. One possibility is that induction of ferroptosis might be combined with 
another redox-compromising therapy to target tumor cells. While NOX1 activity 
specifically has not been implicated in cell death in vivo, several other cell death 
phenotypes do involve NOX induced oxidative stress. Brennan et al. have 
described a role for NOX-produced ROS in NMDA-induced toxicity of 
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hippocampal neurons (Brennan, Suh et al. 2009). NETosis requires ROS 
production from functional NADPH oxidase (gp91) to occur (Fuchs, Abed et al. 
2007). These studies show that NOX-dependent cell toxicity occurs in vivo. 
Combined with our results, and the fact that NOX1 is not implicated in apoptosis 
to which many tumors are already resistant, therapies designed to increase 
NOX1-derived ROS production may be an effective direction for future cancer 
research.  
 
Cancer cell metabolism and cell death 
 We found that inhibition of NADPH production by the PPP, either by a 
small molecule inhibitor or by silencing the PPP enzymes G6PD and PGD, 
rescued Calu-1 and BJeLR cells from ferroptosis. Cancer cells often produce 
increased NADPH for biosynthetic purposes (DeBerardinis, Mancuso et al. 2007; 
Vander Heiden, Cantley et al. 2009). In many systems NADPH production by the 
PPP is also important for maintaining reduced glutathione levels and ameliorating 
oxidative stress in cells (Le Goffe, Vallette et al. 2002; Bensaad, Tsuruta et al. 
2006; Pollak, Dolle et al. 2007) or preventing the induction of pro-death signaling 
cascades (Nutt, Margolis et al. 2005). Our data highlight an alternative role for 
PPP-derived NADPH in driving NOX-mediated ROS production, thereby 
sensitizing cells to ferroptosis.  
 Several recent studies have illustrated that cellular metabolic state may be 
a deciding factor influencing overall cell survival as well as the nature of cell 
death pathways induced. Cells with increased dependence on glycolysis are 
136 
 
more likely to undergo apoptosis following glucose (or growth factor) withdrawal 
compared to cells with a lower reliance on glycolytic metabolism (Vander Heiden, 
Plas et al. 2001). It was also shown that the kinase RIP3 switches TNF-
dependent cell death in mouse cells from apoptosis to necrosis in part because 
of its ability to regulate metabolic enzymes and enhance ROS production (Zhang, 
Shao et al. 2009). Our studies show that in some cancer cells activity of the PPP 
influences the cell to undergo ferroptosis. Cancer cells preferentially generate 
ATP through aerobic glycolysis rather than oxidative phosphorylation and rely on 
non-oxidative glucose metabolism for substrates necessary for cell growth 
(Warburg 1956; Vander Heiden, Cantley et al. 2009). It is curious, however, that  
in the BJeLR and Calu-1 cells studied here cancer cell-produced NADPH 
sensitizes these cells to oxidative cell death, rather than protects cells from 
oxidative stress via maintaining reduced glutathione. It would be interesting to 
uncover why this is so. Wan Seok Yang has gathered data suggesting that 
glutathione is depleted during ferroptosis in an antioxidant-independent manner. 
Perhaps in ferroptosis sensitive cells the loss of glutathione is double-hit on 
cellular redox state, increasing oxidative damage to macromolecules and also 
increasing the pool of unused NADPH available as a substrate to NOX1. 
Alternatively perhaps ferroptosis-sensitive cells have some yet-to-be 
characterized mechanism available for coupling PPP-derived NADPH to NOX1.  
Additionally, not all ferroptosis-sensitive cells tested showed the same 
dependence on the PPP. In HT-1080 cells rescue from ferroptosis by 6-
aminonicotinamide in the metabolic inhibitor panel (Chapter 5) may have been a 
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false positive. This result did not repeat with the same magnitude of rescue in 
later studies, nor did silencing of G6PD or PGD rescue HT-1080 cells for 
ferroptosis. However, HT-1080 cells are rescued by inhibition of NOX1. Thus in 
these cells it appears that the sensitization to ferroptosis is PPP-independent. It 
would be useful to determine if these cells rely on some other pathway for 
NADPH production. In addition to the PPP, several other sources of NADPH 
exist in cells, including production from NADP+ by isocitrate dehydrogenase-1 
and -2 (IDH1/2) enzymes and the malic enzyme (ME) and by NAD-kinases 
(NADK) (Pollak, Dolle et al. 2007; Vander Heiden, Cantley et al. 2009). shRNAs 
targeting several isoforms of both IDH1/2 and ME were included in a recent 
mitochondria-specific shRNA suppressor screen and did not rescue cells from 
ferroptosis (S. Dixon and B.R.S., unpublished). Interestingly however, NADK was 
identified as a potential hit in a kinase library shRNA screen for suppressors of 
ferroptosis several years ago (W. Yang and B.R.S., unpublished). In light of the 
recent findings on the role of NADPH in ferroptosis, it would be interesting to 
revisit a potential role for NADK in ferroptosis as a modulator of NADPH 
homeostasis. 
  
Functional studies of erastin’s effect on VDAC2 
 The VDAC2,3 proteins were originally identified as targets of erastin by 
affinity purification (Yagoda, von Rechenberg et al. 2007). Silencing of VDAC2 or 
VDAC3 expression prevents ferroptosis induced by erastin and RSL5 (but not 
RSL3) in a cell-type-dependent manner, and erastin, but not an inactive analog, 
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was shown to bind to purified hVDAC2 with a Kd of approximately 112 nM. 
However, the effect of erastin on VDAC2 function was not known. To address 
this question, we developed an in vitro model of human VDAC2 (hVDAC2) that 
permits interrogation of functional properties of purified hVDAC2 refolded into 
liposomes. We found that erastin treatment increases the rate of NADH entry into 
liposomes through hVDAC2 with an EC50 of approximately 50 nM. The effect of 
erastin on gating by hVDAC2 is specific to the active erastin scaffold, as erastin 
A8 did not change the rate of NADH oxidation at any concentration tested. 
Previous studies of erastin’s effect on NADH oxidation by purified mitochondria 
expressing mouse VDAC2 but no other isoforms showed that erastin treatment 
decreased the rate of NADH oxidation by mitochondrial NADH oxidase (Yagoda, 
von Rechenberg et al. 2007). However, this decrease was only observed at 
erastin concentrations above 10 "M, well above both the measured Kd with 
VDAC2 and the EC50 for erastin in BJeLR cells. The NADH-coupled gating assay 
described here uses human VDAC2 and the readout does not depend on the 
function of an endogenous enzyme following an extensive mitochondrial 
purification procedure. These differences in the two assays may explain the 
different effects that were observed on VDAC2 permeability following erastin 
treatment. The EC50 for erastin in the NADH-coupled gating assay (50 nM) is in 
good agreement with the previously-measured Kd for erastin binding to VDAC2.  
The NADH-coupled gating assay also allowed us to examine the erastin 
sensitivity of an N-terminal truncation of hVDAC2. #hVDAC2 was insensitive to 
the effect of erastin on NADH gating at submicromolar concentrations. This result 
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shows that the N-terminal helical portion of VDAC2 is necessary for erastin to 
affect hVDAC2 gating, and we speculate that this region of the protein may be 
involved in directly binding to erastin, although this remains to be shown. In 
VDAC1, the N-terminal helix is thought to be involved in gating. A recent crystal 
structure of mouse VDAC1 modeled the glycine-rich connection between this 
helix and the first beta-strand as a flexible hinge which could rearrange in 
response to stimuli and rotate the N-terminal helix into the center of the pore 
where it would be positioned to affect metabolite flux (Ujwal, Cascio et al. 2008). 
While high-resolution structural data for VDAC2 is lacking, an additional benefit 
of the assay we developed is that it also permits examination of hVDAC2 
structure by solid state NMR studies done in collaboration with the McDermott 
group. Future structural studies may further enlighten our understanding on 
where and how erastin interacts with hVDAC2 to affect metabolite flux. Following 
identification of putative erastin-binding residues, the functional assay may be 
used with specific VDAC2 mutants to assess the effect of disrupted erastin 
binding on VDAC2 function.   
 The NADH-coupled gating assay demonstrates that erastin specifically 
affects substrate gating by hVDAC2, and an important question is how altered 
VDAC2 gating induces ferroptosis. The functional assay we developed used 
NADH as a model substrate, but in cells other metabolites or ions may be 
trafficked by VDAC2. The increase in VDAC2 permeability upon erastin treatment 
could potentially be consistent with a model in which labile iron exits the 
mitochondria. Alternatively changes in VDAC2 permeability might affect some 
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other metabolite or overall membrane permeability leading indirectly to release of 
labile iron. Additionally we are not certain of the effects of other VDAC2 
interactors or post-translational modifications on VDAC2 gating behavior. Finally 
the functional effect of erastin on VDAC3, which is not known to gate like the 
other two isoforms (Xu, Decker et al. 1999), remains to be determined.  
 Some cell types we have studied are more reliant on the presence of one 
VDAC isoform than the other for ferroptosis. For example, silencing of VDAC3 is 
more effective at preventing ferroptosis in HT-1080 cells than VDAC2, while 
VDAC2 silencing is quite effective in Calu-1 cells. However in many cell types the 
two targets appear to be functionally redundant as silencing of only one isoform 
does not prevent ferroptosis. It is also possible that erastin targets proteins in 
addition to the VDACs to induce ferroptosis. RSL3 is a small molecule that 
induces a similar iron-dependent oxidative cell death as erastin but cells are not 
rescued from RSL3 upon VDAC knockdown (Yang and Stockwell 2008). Rohitha 
SriRamaratnam is currently working to identify the binding partners of RSL3. It 
will be interesting to evaluate RSL3 receptors for whether they interact with either 
VDACs or erastin. 
 
Erastin’s structure-activity relationship 
 We were interested in understanding the relationship between the parent 
erastin scaffold and induction of ferroptosis in order to know where the molecule 
may be modified for improved pharmacodynamic and pharmacokinetic properties 
or to create tool compounds for future studies. Evaluation of over fifty erastin 
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analogs has enabled us to better define regions of the parent erastin scaffold that 
are critical for activity and regions that may be modified. Furthermore these 
studies have resulted in several very interesting erastin analogs with specific 
potential uses. 9MEW96, which contains a morpholine substituent is over ten-fold 
more soluble in aqueous conditions compared to the parent compound while still 
retaining activity and selectivity in RAS-transformed cells. This analog represents 
an excellent illustration of the positive effect of morpholine solubilizing groups on 
the erastin scaffold and is a good starting point to begin testing erastin analogs 
for prevention or therapeutic benefit in mouse tumor-xenograft models. 
3MEW150 (POX-Tfd-erastin A2) is an erastin analog bearing a photoaffinity 
label. Matt Welsch is planning to use this technique in future studies to further 
evaluate the interaction of erastin with hVDAC2 and try to define a specific 
binding site.  
 
In vivo relevance of ferroptosis 
 Ferroptosis is an iron-dependent oxidative cell death induced by erastin as 
well as RSL3 and RSL5 that is distinct from previously observed forms of cell 
death. Given that ferroptosis represents a novel form of cell death, we are 
curious to identify settings in which ferroptosis occurs in vivo in the absence of an 
exogenous small molecule. The characterization of ferroptosis presented here, 
particularly the identification of NOX1 as a source of ROS, should guide and 
inform these future studies. For example, many studies of cell death have been 
carried out in model organisms such as worms and fruit flies. However, NOX1 
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sequence orthologs are not present in model organisms such as S. cerevisiae, C. 
elegans, or D. melanogaster (although the latter two do express an ortholog to 
one of the NOX superfamily dual-function oxidases) (Cheng, Cao et al. 2001; 
Edens, Sharling et al. 2001). Thus, NOX-dependent ferroptosis should occur 
primarily in mammalian systems and may explain why ferroptosis has not been 
observed in previous studies of model organisms. We have observed that erastin 
is ineffective in inhibiting growth in yeast under a variety of conditions, for 
example, and the requirement for NOX1 activity in ferroptosis is likely one reason 
for this result. 
 It is of great interest to identify naturally-occurring conditions, genes, and 
signals that induce ferroptosis. One possibility to be kept in my during these 
studies is that ferroptosis might only be observed in the presence of an 
exogenous small molecule. However, we think this is unlikely for several 
reasons. First, ferroptosis is induced by several structurally-distinct small 
molecules that bind to different cellular proteins. This observation suggests that 
multiple means exist to induce ferroptosis that lead to a common effector 
pathway, similar to how multiple distinct stimuli may induce apoptosis by initiating 
either the intrinsic or extrinsic pathway but converge on a common set of 
effectors and stereotypic cellular changes to result in death. Second, the 
structural requirements for both erastin and RSL3 (R. SriRamaratnam, W. Yang, 
and B.R.S., unpublished)-mediated ferroptosis are relatively stringent. As 
described in Chapter 4, many changes to the erastin scaffold result in loss of 
activity in our cell culture system. Such stringency suggests binding of the 
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compound to a specific target to mediate the phenotype. Alternative means to 
modulate the target in the same manner should result in the same phenotype. 
Third, erastin-induced ferroptosis is modulatable by multiple genetic effectors that 
are specific to erastin but not other forms of cell death (S. Dixon and B.R.S., 
unpublished). This implies the existence of a specific signaling pathway 
necessary to mediate ferroptosis. Fourth, if studies determine that ferroptosis’s 
primary importance is as a form of tumor cell death, ferroptosis still represents a 
unique and interesting means of eliminating cancer cells with therapeutic 
applications. We do not know whether ferroptosis in vivo will be immune-
stimulatory like other forms of programmed necrosis, but based on the fact that 
the plasma membrane integrity is eventually compromised we speculate that it 
may be (Zong and Thompson 2006; Cho, Challa et al. 2009). The role of immune 
system stimulation and inflammation in response to anti-cancer therapies is 
complex and in some settings is thought to contribute to negative outcomes 
(Degenhardt, Mathew et al. 2006). In other cases, however, anti-cancer therapies 
that lead to immune system activation may be tied to improved therapeutic 
efficacy (Zitvogel, Apetoh et al. 2008; Grivennikov, Greten et al. 2010). It is 
possible that this feature of ferroptosis could be exploited to improve tumor 
immune surveillance. 
 In understanding the in vivo relevance of ferroptosis the example of 
necroptosis serves as a useful precedent. Necroptosis was observed in tissue 
culture for many years upon treatment of mouse fibrosarcoma or human T cells 
with TNF or Fas in the presence of caspase inhibitors (Vercammen, Beyaert et 
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al. 1998; Holler, Zaru et al. 2000). The identification of a small molecule inhibitor 
of necroptosis (Nec-1) in 2005 and its target (RIPK1), greatly advanced the 
studies of programmed necrosis in vivo (Degterev, Huang et al. 2005; Degterev, 
Hitomi et al. 2008; Cho, Challa et al. 2009). Since that time necroptosis has been 
implicated in ischemic injury and the immune response to viral infection, and 
additional regulators of this programmed necrosis signaling cascade have been 
defined (Degterev, Huang et al. 2005; Hitomi, Christofferson et al. 2008; Cho, 
Challa et al. 2009; Upton, Kaiser et al. 2010). Our studies identifying a role for 
NOX1 in ferroptosis have also identified a role for the small molecule inhibitor 2-
APT in preventing ferroptosis. High nanomolar to low micromolar doses of 2-APT 
prevent erastin and RSL3-induced ferroptosis, but not cell death induced by a 
variety of other agents including inducers of apoptosis and oxidative stress 
(Figure 3.2D and not shown). 2-APT might therefore represent a potentially 
useful inhibitor of ferroptosis for in vivo studies, particularly in combination with 
an iron chelator, although further characterization with respect to 2-APT’s actions 
in other cell types and over longer durations of exposure are necessary to 
determine this use. If erastin shows efficacy in future tumor model studies, 2-APT 
could be used to help determine cell populations undergoing ferroptosis. 
Additionally, 2-APT could be used in non-tumor models to identify populations 
susceptible to NOX1-dependent ferroptosis. These types of studies would also 




Appendix A5: Investigations of Ferroptosis in VDAC-
Knockout Mouse Embryonic Fibroblasts 
 To enable cell-based studies of erastin’s activity on VDAC mutants, we 
first wanted to identify a cell type depleted of endogenous VDAC that we could 
use to evaluate ferroptosis. VDAC knockout mice have been generated (Wu, 
Sampson et al. 1999) and used to study the role of VDACs in cell death (Baines, 
Kaiser et al. 2007). We obtained Vdac1-/-, Vdac3-/-, and Vdac1;Vdac3 -/- (dKO) 
mouse embryonic fibroblasts along with wild type matched controls and 
evaluated ferroptosis in these cells. We hypothesized that if these MEFs showed 
differential sensitivity to erastin, these cells might represent a useful background 
in which to express VDAC mutants and study the activity of erastin in a cell-
based experiment. All four cell lines showed similar dose response curves when 
treated with erastin (Figure A.1A). The cell death was DFO- and antioxidant-
sensitive, although less sensitive to MEK inhibition than erastin-induced death in 
cancer cells (Figure A.1B). Thus it seems that erastin-induced death in MEFs 
shares some but not all characteristics with ferroptosis in tumor cells.  
 We were initially surprised by the similar dose-response profile of the 
Vdac3-/- and dKO MEFs, as we had anticipated that these cells would show 
some resistance to ferroptosis given the deletion of VDAC3, an erastin target. 
Using qPCR we evaluated the level of expression of each of the VDAC genes 
across the cell lines (Figure A.1C). In wild-type MEFs, we observed expression of 
                                            
5 I thank Dr. William Craigen (Baylor College of Medicine) for generously 
providing Vdac-knockout MEFs. 
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all three VDAC isoforms, while dKO MEFs only showed expression of VDAC2. 
Surprisingly, the Vdac3-/- MEFs showed about 50% of the level of VDAC3 
transcript when compared to wild-type MEFs. This result repeated across 
multiple experiments. We wondered whether this residual expression of VDAC3, 
or a greater dependence on VDAC2 in MEF-based ferroptosis, could account for 
lack of resistance to ferroptosis in the Vdac3-/- and dKO cell lines. In some tumor 
cell lines, we have previously observed a more significant role for one VDAC 
isoform over the others in ferroptosis (Yagoda, von Rechenberg et al. 2007) (and 
Chapter 3, Figure 3.4).  
 To fully address the roles of VDAC2 and VDAC3 in erastin-induced death 
in MEFs, we used shRNAs targeting VDAC2 and VDAC3 to silence murine 
VDAC2 and VDAC3 in wild-type and Vdac3-/- MEFs. For each gene, we found at 
least three hairpins that depleted mRNA levels by more than 50% (Figure A.1E, 
G). Silencing of VDAC2 did not protect either wild-type or Vdac3-/- MEFs from 
ferroptosis, suggesting that VDAC2 is not required for ferroptosis in these cells 
(Figure A.1D). A single hairpin targeting VDAC3 offered substantial (>80%) 
rescue in wild-type and Vdac3-/- MEFs (Figure A.1F). This hairpin also 
demonstrates the greatest degree of knockdown in cells (Figure A.1G). Further 
studies, including characterization of VDAC3 at the protein level, would be 
needed to evaluate whether the effects of this hairpin are specific to VDAC3. 
However, because ferroptosis in MEFs appears largely VDAC2-independent and 
has unclear dependence on VDAC3, we concluded that this system would not be 
optimal for testing ferroptosis-induction by mutant VDAC2 isoforms.  
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Figure A.1: Ferroptosis in MEFs is Independent of VDAC2 Expression 
 
 
Figure A.1: Ferroptosis in MEFs is Independent of VDAC2 Expression. A) 
Response of wild-type, Vdac1-/-, Vdac3-/-, and dKO (Vdac1-/-;Vdac3-/-) mouse 
embryonic fibroblasts to erastin. B) Wild-type MEFs are rescued from ferroptosis 
by an iron chelator (DFO, 100 "M) and an antioxidant (BHA, 15 "M), but not by a 
MEK inhibitor (U0126, 13 "M). C) Relative mRNA expression of mouse VDAC1, 
148 
 
VDAC2, and VDAC3 in different cell contexts. D and F) Growth inhibition of wild-
type and Vdac3-/- MEFs by erastin (4.6 "M) following shRNA knockdown of 
mouse VDAC2 (D) or VDAC3 (F). Hairpin numbers are indicated below graphs. 
E) and G) Relative mRNA expression of mVDAC2 (E) and mVDAC3 (G) 




The role of VDACs in erastin’s mechanism of action was also evaluated 
using VDAC-knockout MEFs. Treatment of these cells with erastin resulted in 
ferroptosis that is MEK- and VDAC2-independent. The role of VDAC3 in MEF-
based ferroptosis is less clear as the VDAC3-null MEFs are of similar erastin-
sensitivity to wild-type but still appear to express about 50% the transcript. 
Furthermore a single hairpin targeting VDAC3 rescues wild-type and VDAC3-null 
MEFs from ferroptosis. One possibility is that even a small amount of VDAC3 
expression in these cells is sufficient for ferroptosis. Alternatively, it is possible 
that erastin-induced ferroptosis in mouse cells is more dependent on another 
target than on the VDACs. The small molecule RSL3 also induces ferroptosis in 
a VDAC-independent manner. Given that ferroptosis in MEFs is MEK-
independent, these cells may depend on a slightly different set of signals than 
human cancer cells to result in a similar death phenotype.  
 
Materials and Methods 
MEF cell culture 
MEFs (wild-type, Vdac1-/-, Vdac3-/-, and Vdac1-/-;Vdac3-/- double knockouts) 
were obtained from Dr. William Craigen (Baylor COM). 293T cells were obtained 
from American Type Culture Collection. MEFs were grown in DMEM 
supplemented with 10% fetal calf serum. 293-T cells were grown in DMEM High-
Glucose supplemented with 10% FBS. When used for transfections to generate 
virus, 293-T cells were seeded in the above media lacking antibiotics.  293-T viral 
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collection media contained 30% HyClone FBS. All cell lines were grown in 
humidified tissue culture incubators (Thermo Scientific) at 37oC with 5% CO2.  All 
medias were supplemented with penicillin and streptomycin (Gibco). 
 
Knockdown and qPCR experiments were performed according to the methods 
described in Chapter 3. For qPCR, samples were normalized to the mouse 





Appendix B6: Studies Using an Erastin Probe to Identify 
the Erastin Binding Site on VDAC2 
To discover the erastin binding site on VDAC proteins, our initial strategy 
was to synthesize analogs of erastin that bind covalently to the VDAC proteins 
and identify the labeled regions of the protein by mass spectrometry. Our 
strategy entailed the introduction of an electrophilic chloroacetyl moiety, which 
would be susceptible to attack from nucleophillic residues present in the erastin-
binding region of the VDACs (i.e. cysteine, serine, threonine). Previous work on 
erastin’s structure-activity relationship demonstrated that modifications to position 
7 on the quinazolinone system are tolerated, which made this position an ideal 
choice for the introduction of this group. In order for the compound to be tagged 
with azide-linked fluorophores using copper-catalyzed azide-alkyne cycloaddition 
chemistry (Figure B.1A) (Speers, Adam et al. 2003), the ethoxy group of erastin 
was substituted for a propargoxy group.  
Starting from 4-nitroanthranilic acid, the erastin synthesis described in 
Yagoda et al. was followed with slight variations. In the third step of the 
synthesis, an o-aminophenol group was used in the condensation rather than o-
ethoxyaniline. Subsequently the phenolic hydroxyl group was propargylated 
using propargyl bromide. In the second to last step of the synthesis the nitro 
group was reduced to an amine. This group was then chloroacetylated with 
                                            
6 I thank Dr. Tijana Talisman-Jovanovic (Chait Lab, Rockefeller University) for 
assistance with mass spectrometry experiments described in Figure A.2C. 
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chloroacetyl chloride to give the final product. Initially all reactions were 
monitored by thin layer chromatography and LC-MS. Proton NMR spectra were 
taken following each purification step and assigned as well. 
 The final product (which will be referred to as the probe) was tested for its 
biological activity. Several assays were used to evaluate the activity of the probe 
and compare it to erastin. First, a cell viability assay using alamar blue 
demonstrated that the probe retains oncogenic RAS-selective lethal activity 
(Figure B.1B). Although the EC50 of the erastin probe in BJeLR cells was 
approximately three-fold higher than the EC50 of erastin, a window of threefold 
selectivity for BJeLR cells over BJeH was retained. Additionally lethality by the 
probe (20 "M) was prevented by co-treatment with an iron-chelator 
(deferoxamine, DFO), an antioxidant (butylated hydroxyanisole, BHA) or a MAPK 
inhibitor (U0126) prevented growth inhibition of BJeLR cells by the probe (Figure 
B.1C). These results suggest that the probe, while less potent than erastin, 
retains a similar mode of cell death and should act through the same molecular 
targets as erastin.  
153 
 
Figure B.1: Synthesis of and characterization of erastin probe 
 
Figure B.1: Synthesis of and characterization of erastin probe. A) Synthesis 
of erastin probe (propargoxy-chloroacetamide-erastin). (i) Propionyl chloride, 
DMF, 0˚C!RT, overnight, (40%). (ii) acetic anhydride, reflux (>180˚C), 48 hours, 
(87%). (iii) 2-aminophenol, diisopropylethylamine (0.9 mEq), CHCl3, N2(g), reflux 
overnight. (iv) propargyl bromide, K2CO3, acetone, reflux overnight (54%). (v) Br2 
(1.1 mEq), 50:1 NaOAc:acetic acid (glacial), 40˚C, 12 hours (99%). (vi) 
piperazine (3.5 mEq), ethanol, reflux overnight. (vii) 4-chlorophenoxyacetyl 
chloride, triethylamine (3 mEq), CH2Cl2, overnight. (viii) Fe(0), acetic acid 
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(glacial) (1 mEq), 4:1 THF:H2O, reflux 2 hours, (10%). (ix) Chloroacetyl chloride, 
triethylamine, CH2Cl2, RT, (100%). Overall yield for synthesis, given inadvertent 
substantial loss at step vi was < 0.1%. B) Growth inhibition by probe compared to 
erastin in BJ/TERT/LT/ST/RASV12 (BJeLR) and BJ/TERT (BJeH) cells. C) Growth 
inhibition by probe and erastin, each at 20 ug/ml, in BJeLR cells cotreated with 
DMSO, deferoxamine (DFO, 100 "M), butylated hydroxyanisole (BHA, 15 "M), 




Based on these results, we proceeded to use the probe to investigate the 
erastin-VDAC2 interaction. We used the probe in studies on both purified VDAC2 
protein or on intact cells (Figure B.2A). N-terminally His6-tagged VDAC2 was 
expressed recombinantly, purified from inclusion bodies, and refolded into 
liposomes using a 1:1 mixture of phosphatidylcholine:phosphatidylserine. 
Liposomes incorporating VDAC2 were treated with probe at room temperature 
for one hour. To detect probe-labeled protein on a gel, a fluorescent tag such as 
rhodamine-azide or fluorescein-azide was then appended to the terminal alkyne 
on the probe by the copper-catalyzed azide-alkyne cycloaddition (Speers, Adam 
et al. 2003). The cycloaddition reaction was allowed to progress for an hour at 
room temperature, and the products were run on an SDS-polyacrylamide gel.  In-
gel fluorescence demonstrated probe-labeled protein (Figure B.2B, lane 1 and 
lane 3). The experimental conditions were modified over several experiments to 
improve signal intensity while decreasing background fluorescence from the 
rhodamine-azide tag, which was observed to form SDS-stable complexes with 
the protein when used at high concentrations (not shown).   
 Several trials were performed to assess specificity of probe labeling of 
VDAC2. To minimize the possibility of non-specific labeling, the ratio of the 
protein:probe was adjusted to 2:1.  We first tested whether the labeling reaction 
could be abolished by addition of chloroacetamide-erastin, an erastin analog 
bearing a chloroacetamide moiety at the same position on the quinazolinone 
system but lacking the propargyl site for tagging. Purified VDAC2 protein was 
pretreated with a twenty-fold excess of chloroacetamide-erastin (relative to 
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probe) for twenty minutes prior to addition of the probe (Figure B.2A and B.2B 
lanes 7-9). We did not observe a significant decrease in the in-gel fluorescence 
intensity during these experiments. This result demonstrated that the 
chloroacetamide-erastin competitor does not react with all possible probe-
labeling sites on VDAC2. Several other methods were evaluated in an effort to 
compete off the labeling signal. VDAC2 was pretreated with iodoacetamide—a 
commonly employed cysteine-alkylating agent (Wulff, Siegrist et al. 2007)—at 
concentrations of 100 to 1000-fold excess of the probe. In these experiments, a 
decrease in the in-gel fluorescence signal was occasionally observed but was not 
reproducible from one experiment to the next (data not shown). Another type of 
quenching reagent we tested, beta-mercaptoethanol--which should inactivate the 
chloroacetamide electrophile on the probe—interfered with the azide-alkyne 
cycloaddition reaction and therefore did not accurately reflect a decrease in 
probe-labeling of VDAC2. 
 There were several possibilities as to why the fluorescent signal was not 
quenchable under the conditions tested. First, the probe might bind non-
specifically to surface-exposed nucleophilic side chains in VDAC2. To minimize 
this possibility, we repeated several of the competition experiments using a 10:1 
ratio of VDAC2:probe. With such a low amount of probe, in-gel fluorescence 
could not reliably detect labeled protein and we instead monitored the reaction by 
western blotting for a fluorescein-azide tag. These experiments still did not 
demonstrate a decrease in chemiluminscent signal between probe-only and 
competitor-pretreated samples. Second, it was possible that in flash-refolding the 
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VDAC2 protein into liposomes, a few subpopulations of folding states were 
generated including one that might be susceptible to labeling by multiple 
molecules of probe per monomer of protein. Finally there remained the possibility 
that the labeling reaction was inefficient under the conditions being tested and 
the signal differential in competing off such a low level of fluorescence would not 
be detectable under the conditions used. 
To assess the efficiency of the in vitro labeling reaction and to begin to 
identify probe-binding peptides, we began collaborating with the Chait Lab at 
Rockefeller University to perform mass spectrometry-based analysis of purified 
VDAC2. Using an ultrathin layer MALDI sample preparation technique 
appropriate for membrane proteins (Cadene and Chait 2000), we studied 
samples of full-length VDAC2 by MALDI-TOF (Figure B.2C). No differences in 
peak appearance or width were observed when comparing probe-labeled protein 
samples to unlabeled protein. Additional studies were carried out using an 
increased ratio of probe:VDAC2 (10:1), but these also did not show a shift in the 
average mass of protein treated with probe. These observations suggested that 




Figure B.2: Studies on VDAC2 Labeling by Erastin Probe 
 
Figure B.2: Studies on VDAC2 Labeling by Erastin Probe. A) Schematic of 
labeling of purified VDAC2 or VDAC2 in living cells with probe. Labeling was 
done in the presence or absence of 20x competitor (chloroacetamide erastin). B)  
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Probe labeling of purified VDAC2 in the presence or absence of competitor. 
VDAC2 refolded into liposomes was incubated for 20 minutes in the presence or 
absence of 10x competitor, followed by addition of either DMSO or 1x probe for 
the times indicated. At the end of the incubation, samples were flash frozen in 
liquid nitrogen and placed on ice prior to click chemistry coupling of rhodamine-
azide tag. BSA was present in select samples to minimize non-specific labeling 
of hVDAC2 by probe. Samples were run on SDS-PAGE and visualized by in-gel 
fluorescence scanning. This experiment was repeated twice in triplicate. C) 
MALDI-TOF spectra on full-length purified VDAC2 or probe treated VDAC2. 
Values for peaks are listed to the right. D) In-cell labeling using probe. BJeLR 
cells were treated with DMSO (D) or Probe (P) for one hour, or with 20 ug/ml 
chloroacetamide-erastin competitor for twenty minutes followed by probe for one 
hour (C/P). Cells were lysed by hypotonic lysis and the rhodamine tag was 
appended to labeled proteins by azide-alkyne cycloaddition. Labeled VDAC2 
protein was also run on the gel as a control for detection (+). Arrows indicate 
protein bands on gel that display a loss of fluorescence in the presence of 
competitor. E) Probe labels proteins in mitochondria (P) as well as the cytosol 
(S). In-cell labeling was carried out and cells were fractionated prior to tag 
addition. Total cell lysate (T) is shown for comparison. Arrows indicate protein 
bands with differential fluorescence comparing S and P fractions. F) Western blot 
showing that under the fractionation conditions used, VDAC2 is present in the 
pellet (P) rather than the supernatant (S). Actin was used as a loading control. G) 
Trial affinity purification of VDAC2 using probe. Cells were treated with probe, 
mitochondria were purified, and fluorescein-azide tag was added by azide-alkyne 
cycloaddition. Western blot shows signal from fluorescein tag in: mitochondrial 
pellet (P), after desalting column (ds), flow-through off anti-fluorescein beads 
(FT), wash (W), and elutions (E1, E2.) H) Western blot against same samples as 
in (G) using a pan-VDAC antibody that can detect all three VDAC isoforms. A 




Next, we were curious as to whether the erastin-VDAC interaction might 
be better studied under in-cell conditions, in which VDACs are present in the 
context of the mitochondrial outer membrane with native lipids and binding 
partners. We decided to use the probe to purify VDAC isoforms and associated 
binding partners from cells (Figure B.2A). These experiments would validate 
erastin’s interaction with VDACs in cells and allow us to observe how VDAC’s 
interacting partners change upon erastin treatment. Furthermore VDAC3 has 
been difficult to study in vitro but may be more amenable to cell-based 
investigations.  
When BJeLR tumorigenic fibroblasts were treated with probe, a number of 
proteins were labeled (Figure B.2D). Several of these labeling events appeared 
to be specific as the fluorescence intensity of several bands decreased when 
cells were pretreated with ten-fold higher concentration of chloroacetamide-
erastin. We were interested in learning whether any of the specifically labeled 
bands corresponded to VDAC2/3. As a first step we decided to see whether 
mitochondrial proteins were labeled by the probe. Cells were treated with probe 
and then fractionated prior to addition of the rhodamine-azide tag. Probe-labeled 
proteins appear in both the supernatant and the mitochondria-containing pellet of 
the fractionation, however several darker bands were apparent in the pellet 
(Figure B.2E). We also western-blotted for VDAC2 following fractionation and 
demonstrated that VDAC2 fractionates into the pellet (Figure B.2F). This 
experiment demonstrated that mitochondrial proteins are labeled when intact 
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cells are treated with probe and that the VDAC proteins are among the 
mitochondrial fraction.  
Next we used the probe to affinity purify the VDACs from cells. In these 
experiments, cells were treated with probe and subsequently the mitochondria 
were purified from the cytosolic fraction. The mitochondrial fraction was then 
tagged with fluorescein-azide (Figure B.2G). Excess free fluorescein-azide was 
removed by spin column, and mitochondrial lysates were incubated over an anti-
fluorescein antibody-linked affinity resin. Elutions from this resin were western 
blotted for the VDAC proteins and for fluorescein (Figure B.2G, H). This 
experiment was performed both on cells expressing endogenous VDACs and 
cells expressing a VDAC2-V5 fusion protein. Up to this point, we were not able to 
affinity purify probe-labeled VDAC proteins. Given that the mass spectrometry 
data on purified VDAC2 suggested that the probe-labeling reaction was 
inefficient, this is perhaps not surprising. At this point, we turned to several 
alternative strategies to evaluate the erastin-VDAC interaction.  
 
Discussion 
Here I describe a chemical affinity labeling strategy using POX-CAM-erastin as a 
probe molecule for identification of the erastin binding site on VDAC2. This probe 
showed reduced potency in BJeLR cells and decreased selectivity (Table 4.1). 
While the probe synthesis was initially followed by TLC and LC-MS, NMR data 
suggests that this synthesis may have resulted in a mixture of products. 
Specifically the bromination step may have led to alternatively brominated or 
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poly-brominated products that were not detected by mass spectrometry. While 
the probe labeled purified VDAC2, the signal was not specific and showed low 
efficiency of labeling in MALDI studies. The probe was tested as a label for 
VDAC in living cells, but VDAC2 was not affinity purified using this probe. Affinity 
labeling target proteins either in lysates or living cells has been successful 
previously (Karlin and Winnik 1968; Chen, Heim et al. 2003; Cohen, 
Hadjivassiliou et al. 2007). The probe compound used in these studies may 
simply not have been the optimal choice for a few reasons. First, electrophilic 
groups such as the chloroacetamide used in the probe would undergo reaction 
with nucleophilic protein side chains, likely by an SN2-like mechanism. For 
efficient binding site labeling, this probe requires that a nucleophilic side chain 
(such as cysteine, serine, or threonine) be present with the correct geometry in 
the binding site. While VDAC2 is rich in serine (23) and threonine (31), it contains 
9 cysteines. Second, this probe showed decreased potency and selectivity in 
cells. This may be due to non-specific reactivity of the electrophile with other 
macromolecules or due to the potential mixture of compounds discussed above. 
For both of these reasons an erastin analog containing a photoaffinity label 
seems like a promising choice for future studies. 
 
Materials and Methods 
Cell culture 
BJ/TERT/LT/ST/RASV12 (BJeLR) and matched controls were obtained from 
William Hahn (Harvard University). BJ cells were grown in DMEM High-Glucose 
media (Gibco) plus 20% M199 (Sigma) and 15% heat-inactivated fetal bovine 
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serum (FBS). All cell lines were grown in humidified tissue culture incubators 
(Thermo Scientific) at 37oC with 5% CO2.  All medias were supplemented with 
penicillin and streptomycin (Gibco). 
 
 
Purification of hVDAC2 
VDAC2 expression, purification, and reconstitution into liposomes is described in 
Chapter 4.  
 
Labeling of hVDAC2 in liposomes with erastin probe 
To label purified VDAC2 in liposomes with the probe, 1 ml samples of 
hVDAC2 refolded into liposomes were dialyzed into 10 mM phosphate buffer (pH 
8.0) overnight with 2 changes of buffer. Protein concentration in resuspended 
liposomes was determined after dialysis by SDS-PAGE comparison to a BSA 
standard dilution series. Samples for labeling reaction were 50 "l volume with a 
protein concentration of 6 "M. Samples were incubated with probe (3 "M) at 
room temperature for varying lengths of time (5 min-1 hour) followed by freezing 
in liquid nitrogen to stop probe labeling. The tagging reaction was performed 
using rhodamine-azide tag (5 "M) in the presence of 1 mM TCEP, 100 "M 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA; ligand) and 1 mM 
CuSO4 for 1 hour at room temperature. Aliquots (15 "l) from each reaction were 
mixed with 5x SDS loading buffer (250 mM Tris-HCl pH 7.5, 50% glycerol, 0.5 M 
DTT, 10% SDS, bromophenol blue) and run out by SDS-PAGE. Samples were 
visualized by in-gel fluorescence scanning using a Typhoon Trio (Ex: 532 nm; 
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Em: 580 BP 30). Samples prepared using a competitor were preincubated for 20 
minutes with 60 "M competitor prior to addition of probe (3 "M). In selected 
reactions BSA was added in equimolar ratio to VDAC2 in order to decrease the 
possibility of non-specific labeling by the probe. 
 
In-cell labeling with erastin probe and pull down trials 
 To label cellular proteins with erastin probe, 2x106 BJeLR cells in a 10 cm 
dish were treated with 2 ug/ml probe (or DMSO) for 1 hour in either normal media 
or media containing 1% serum. After 1 hour, media was removed and cells were 
trypsinized and pelleted at 1000 rpm for 5 minutes, then washed twice using cold 
PBS. After the second wash, cells were transferred to a 1.5 ml Eppendorf tube, 
pelleted at 300 rpm in a benchtop microcentrifuge, and resuspended in 300 "l 
cold PB buffer (10 mM phosphate buffer pH 8.0). Tubes were place on ice for 5 
minutes and cells were then lysed through a 30-gauge needle using a 1 ml 
syringe. Lysates were spun at 10,000 rpm for 10 minutes at 4˚C in a benchtop 
microcentrifuge. 200 "l of each supernatant was removed and the pellet was 
discarded. Protein content was measured using the Bradford assay in 
comparison to a BSA standard and sample protein concentration was normalized 
to 2 mg/ml. Samples were then subjected to copper-catalyzed tagging reaction 
(75 "M rhodamine-azide, 1 mM TCEP, 100 "M TBTA and 1 mM CuSO4 for 1 
hour at room temperature. Aliquots (15 "l) from each reaction were mixed with 5x 
SDS loading buffer and run out by SDS-PAGE. Samples were visualized by in-
gel fluorescence scanning using a Typhoon Trio (Ex: 532 nm; Em: 580 BP 30). 
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Samples prepared using a competitor were preincubated for 20 minutes in media 
containing 20 "g/ml competitor. Media was then removed and replaced with fresh 
media containing 20 "g/ml competitor and 2 "g/ml probe.  
 
Fractionation of mitochondria  
 To enrich for mitochondrial proteins (VDACs) in samples destined for 
affinity purification, cells were fractionated to purify mitochondria. Cells (~ 10 x 
106 in a T175 flask) were treated with probe as above, but following hypotonic 
lysis through needle, sucrose was added to each sample to a final concentration 
of 250 mM. Samples were placed on ice for 15 minutes and spun at 700 x g for 5 
minutes. The supernatant was then spun at 10,000 x g for 15 minutes at 4˚C. 
The pellet (mitochondrial fraction) was resuspended in 300 "l PB + sucrose (10 
mM PB, 250 mM sucrose) and total protein was quantitated by Bradford assay. 
After the Bradford assay a small amount of NP-40 was added (final conc 1%) to 
improve solubility of membrane proteins. The tagging reaction (using fluorescein-
azide, 75 "M) was performed for 1 hour and excess tag was removed by 
desalting column (Zeba Desalting columns, Promega).  
 
Affinity pull-down of probe labeled proteins 
 Anti-fluorescein beads were prepared by coupling NHS-activated 
Sepharose 4 Fast Flow matrix (GE Healthcare) to mouse IgG anti-FITC (Jackson 
Labs) according to the manufacturers instructions. As a control, “negative” beads 
were prepared that had the NHS-active site blocked with ethanolamine. The 
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bead preparations were tested for the ability to affinity purify a positive control 
protein (FITC-tagged goat anti-rabbit IgG (Jackson labs)).  
 For affinity purification of probe labeled proteins, samples off the desalting 
column were brought up to 500 "l final volume by addition of PBS. Samples were 
incubated with anti-fluorescein beads (~30 "l packed beads) overnight at 4˚C on 
a rotator. Supernatant was removed the next morning. The beads were washed 
in 2x 500 "l cold TBSN (Tris-HCl pH 7.5, NaCl, 1% NP-40), 1x 500 "l TBS, and 
eluted. Two elutions were done. The first elution used low pH (60 "l 200 mM 
glycine pH 2.5) and the second used 1x SDS, boiled for 10 minutes. Samples (15 
"l) from each step of the lysis, fractionation, and affinity purification were mixed 
with 5 "l 5x SDS loading buffer and run on a 4-12% Bis-Tris gel in 1x MES buffer. 
Western blotting was performed using anti-fluorescein-HRP (Invitrogen) and anti-
VDAC (Affinity BioReagents, #PA1-46385).  
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Appendix C: Tables of shRNA sequences and qPCR 
primers used in this work 
Gene shRNA Clone Name Target Sequence Notes 
PPIF 1 NM_005729.3-455s1c1 CGCTTTCCTGACGAGAACTTT  
 2 NM_005729.3-648s1c1 GCTCTAAGAGTGGGAGGACAT  
 3 NM_005729.3-664s1c1 GACATCCAAGAAGATTGTCAT  
     
RIPK1 1 NM_003804.x-1674s1c1 CAGCACAAATACGAACTTCAA  
 2 NM_003804.x-1470s1c1 CAGGCCAATTCCAAGTCATAT  
 3 NM_003804.x-432s1c1 CCTTGTTGATAATGACTTCCA  
 4 NM_003804.x-1211 CTTACAACAGAGAGGAGGAAA  
     
VDAC2 1 NM_011695.1-879s1c1 CACTGCTTCCATTTCTGCAAA 
No longer 
available 
     
VDAC3 1 NM_005662.3-263s1c1 CAGGCAACCTAGAAACCAAAT  
     
G6PD 4 NM_000402.2-1914s1c2 CCCTATATTTATGGCAGCCGA  
 5 NM_000402.2-1955s1c2 GCTGATGAAGAGAGTGGGTTT  
     
PGD 1 NM_002631.2-135s1c2 CCAGAACTTAATTCTGAACAT  
     
NOX1 1 NM_007052.3-467s1c1 CCGCACACTGAGAAAGCAATT  
 2 NM_007052.3-519s1c1 GCCTATATGATCTGCCTACAT  
 3 NM_007052.3-563s1c1 CCTGTTTAACTTTGACTGCTA  
 4 NM_007052.3-1572s1c1 GAACAGGAGATGGAGGAATTA  
     
NOXO1 1 NM_144603.2-307s1c1 TGCAGATCAAGAGGCTCCAAA  
 2 NM_144603.2-462s1c1 GTTCTCCCAAAGCTTCTCGAT  
 3 NM_144603.2-473s1c1 GCTTCTCGATGCACCACTGTT  
 4 NM_144603.2-1034s1c1 GCGCGTGTTGGAAACGTCAGA  
     
mVDAC2 1 NM_011695.1-1262s1c1 GCTACCCACCAATGATGGAAA  
 3 NM_011695.1-444s1c1 TCAAGGTTTGAAACTGACTTT  
 4 NM_011695.1-545s1c1 GCTGTGATGTTGACTTTGATT  
     
mVDAC3 2 NM_011696.1-367s1c1 ACTCTTGATACCATATTTG  
 3 NM_011696.1-613s1c1 CTGCATACTCACGTGAATG  
 4 NM_011696.1-1149s1c1 GAGTTCTGCAGAGTTAATT  




Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
PPIF AGGCAGATGTCGTCCCAAAG TGTAGCCGAAGCCCTTCTCA 
RIPK1 AATGGCGGCACCCTCTACTA TCCGACTTCTCTGTGGGCTTT 
VDAC3 AATTTCGCCCTGGGTTACAA AATTCAGTGCCATCGTTCACAT 
VDAC2 TCATATGCTGACCTTGGCAAAG CCAACCCAAAACCAAATCCTT 
G6PD GTGAGGCCTGGCGTATTTTC GGATGGGCTTGGGCTTCT 
PGD CCTAACCGCTACTGGCTGTGT GATCTTTCCCTCTAAATCCCAGATC 
NOX1 TTGCAGCCGCACACTGA GGCCACCAGCTTGTGGAA 
NOXO1 GCAGCCCTGGTGCAGATC TCTGACCAGCGCACAGAGAA 
RPS29 (m) CAACCGCCACGGTCTGA GCACTGGCGGCAACATGT 
VDAC1 (m) CTCCCACATACGCCGACTT GCCGTAGCCCTTGGTGAAG 
VDAC2 (m) ACCTCGCTTGGACATCAGGTA TCCAACTGGTATTTAGCTGCAATG 
VDAC3 (m) TTCTGGACCGACCATCTATGG CCAGCAAGCCAACCTTCAAA 
   
Primers for verifying rho zero status   
MT-12S ATCACTGCTGTTTCCC GCTGGCACGAAATTGACCAA 
MT-ND1 CACCGCCCCGACCTT GGCTAGAATAAATAGGAGGCCTAGGT 
MT-ND3 TCGAAGCCGCACTCGT GGGTAAAAGGAGGGCAATTTCTAGA 
MT-ND4 CTCCTGAGCCAACAAC GGGAGTCATAAGTGGAGTCCGT 
MT-CYB CCCTCGGCTTACTTCT GGGTTGGCTAGGGTATAATTGTCTG 
MT-CO1 TAGCTGCTGGCATCACT GGGTCGAAGAAGGTGGTGTT 
MT-ATP6 ACTGCAGGCCACCTAC GCGACAGCGATTTCTAGGATAGT 
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